Type 2 Diabetes Mellitus

On this page

Quick Reference

RxDrug of choiceMetformin 500-1000 mg twice daily (first-line for most patients without cardiorenal disease)

AltAlternativesSGLT2 inhibitors (empagliflozin 10-25 mg daily, canagliflozin 100 mg daily, dapagliflozin 10 mg daily); GLP-1 receptor agonists (liraglutide 1.8 mg daily, semaglutide 0.5-1.0 mg weekly, tirzepatide 2.5-15 mg weekly); DPP-4 inhibitors (sitagliptin 100 mg daily); basal insulin (glargine, degludec)

⊘AvoidMetformin if eGFR <30 mL/min/1.73 m²; saxagliptin in patients with heart failure; thiazolidinediones in NYHA class III-IV HF; SGLT2i should be held during acute illness or 24-72 h before elective surgery

DxTest of choiceHbA1c (≥6.5%) for initial diagnosis when not affected by hemoglobinopathies or anemia; 75-g OGTT with 2-hour glucose ≥200 mg/dL as gold standard for borderline cases

ScKey scoreWATCH-DM score for 5-year heart failure risk; age at diagnosis for overall mortality risk (each year earlier increases risk by 4%)

→When to referEndocrinology if atypical (lipodystrophy, monogenic diabetes, type 1/LADA uncertainty); nephrology if eGFR <30 or progressive albuminuria; ophthalmology for annual dilated eye exam or if retinopathy detected; bariatric surgery evaluation if BMI ≥35 (or ≥30 with poor control)

T2DM is a heterogeneous disease requiring early intensive glycemic control and cardiorenal protection; SGLT2 inhibitors and GLP-1 receptor agonists reduce major adverse cardiovascular events and slow CKD progression independent of glucose lowering.

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder driven by progressive beta-cell dysfunction on a background of insulin resistance, affecting over 537 million adults worldwide. Management has shifted from a glucose-centric to a complication-centric paradigm: SGLT2 inhibitors and GLP-1 receptor agonists now provide organ protection independent of glycemic control, reducing heart failure hospitalizations by up to 50% and slowing CKD progression by 30%. Early detection, aggressive lifestyle modification, and individualized pharmacotherapy targeting glycemic, cardiovascular, and renal endpoints are essential to alter the disease trajectory and prevent long-term complications.

Overview and Recommendations

Background

•Type 2 diabetes mellitus (T2DM) is a heterogeneous syndrome defined by hyperglycemia resulting from progressive insulin resistance and beta-cell failure, accounting for approximately 90% of diabetes cases globally and affecting an estimated 537 million adults, a prevalence that has more than doubled in the past three decades.
•The pathophysiologic cascade involves five integrated defects: insulin resistance in liver, muscle, and adipose tissue; progressive beta-cell secretory dysfunction with 30-60% mass loss; alpha-cell glucagon dysregulation causing inappropriate hepatic glucose output; a blunted incretin axis (reduced GLP-1 secretion and impaired GIP response); and chronic low-grade inflammation driven by adipose-tissue macrophages, altered gut microbiota, and mitochondrial dysfunction.
•Data-driven clustering has identified five reproducible subtypes, severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD), which differ in age at diagnosis, BMI, complication risk (SIRD highest for nephropathy, SIDD for retinopathy), and therapeutic response.
•The landmark UKPDS and its 10-year follow-up (the legacy effect) demonstrated that early intensive glycemic control with sulfonylurea, insulin, or metformin reduced long-term myocardial infarction by 15% and all-cause mortality by 13%, establishing the principle that early metabolic memory determines future cardiovascular outcomes.
•The therapeutic revolution driven by SGLT2 inhibitors (CREDENCE: canagliflozin 100 mg daily reduced end-stage kidney disease by 32%, HR 0.68) and GLP-1 receptor agonists (LEADER: liraglutide 1.8 mg daily reduced cardiovascular death by 22%, HR 0.78) has moved the goal from glucose lowering to organ protection, with NNTs for cardiorenal outcomes as low as 18-56 over 2-4 years.
•Age at diagnosis is the single most powerful risk stratifier: each 1-year increase in age at diagnosis reduces all-cause mortality by 4%, macrovascular disease by 3%, and microvascular disease by 5%, meaning a patient diagnosed at age 40 carries substantially higher lifetime risk than one diagnosed at age 60, independent of current HbA1c.

Evaluation

•Suspect T2DM in any patient with classic symptoms (polyuria, polydipsia, unintentional weight loss), incidental hyperglycemia, or risk factors (age ≥45, BMI ≥25, family history, hypertension, history of gestational diabetes, PCOS, or South Asian ethnicity).
•Establish the diagnosis using any of the four ADA criteria: HbA1c ≥6.5% (48 mmol/mol), fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test (OGTT), or random glucose ≥200 mg/dL (11.1 mmol/L) with classic symptoms; confirm with repeat testing unless unequivocal hyperglycemia is present.
•Order HbA1c as the first-line diagnostic test for most patients; when HbA1c is unreliable (hemoglobinopathy, anemia, CKD stage 4-5, pregnancy, recent transfusion), use fasting glucose or OGTT instead.
•If HbA1c or fasting glucose is borderline (5.7-6.4% or 100-125 mg/dL), perform a 75-g OGTT to classify prediabetes or overt diabetes; a 1-hour postload glucose ≥155 mg/dL (8.6 mmol/L) identifies individuals at high risk for progression even before HbA1c becomes abnormal.
•Assess the full metabolic profile: fasting lipid panel, liver function tests (with liver ultrasound or transient elastography if NAFLD suspected), serum creatinine and eGFR, urine albumin-to-creatinine ratio, thyroid-stimulating hormone, and vitamin D levels.
•Screen for microvascular complications at diagnosis: dilated eye examination for retinopathy, 10-g monofilament test and vibration sense for peripheral neuropathy, and urine ACR plus eGFR for nephropathy.
•Stratify cardiovascular risk using validated tools: the WATCH-DM score (integrating weight, age, hypertension, creatinine, HDL-C, fasting glucose, QRS duration, MI, and CABG history) predicts 5-year heart failure risk; age at diagnosis under 40 years identifies highest lifetime risk.
•Consider diabetes subtype in atypical presentations: low C-peptide in the setting of hyperglycemia suggests autoimmune diabetes (type 1 or LADA); insulin requirement >100 U/day in a non-obese patient should prompt evaluation for familial partial lipodystrophy (check LMNA and PPARG mutations).
•In women with PCOS, use a 75-g OGTT for screening rather than HbA1c or fasting glucose alone, as isolated fasting glucose misses up to one-third of glucose intolerance; in women with prior gestational diabetes, postpartum OGTT should never be deferred.
•Evaluate for common comorbidities: depression (PHQ-9, bidirectional risk with T2DM), obstructive sleep apnea (STOP-Bang), metabolic dysfunction-associated steatotic liver disease (MASLD, pooled prevalence ~57%), and hyperuricemia or gout (prevalence ~22%).
•In older adults, consider the BMI paradox, overweight (BMI ≥30) may appear protective but central obesity (waist circumference ≥100 cm men/≥95 cm women) predicts higher risk; screen for frailty, cognitive impairment, and hypoglycemia risk before setting glycemic targets.
•For hospitalized patients with hyperglycemia, measure HbA1c to distinguish newly diagnosed diabetes from stress hyperglycemia, and initiate basal-bolus insulin (glargine once daily plus rapid-acting before meals) over sliding-scale insulin to reduce postoperative complications.
•In patients on SGLT2 inhibitors presenting with nausea, vomiting, or unexplained acidosis, check serum ketones and the anion gap regardless of glucose level, euglycemic diabetic ketoacidosis is a treatable emergency that is missed when hyperglycemia is absent.

Management

•Initiate intensive lifestyle modification at diagnosis: goal of ≥150 minutes per week of moderate-to-vigorous physical activity, dietary counseling to achieve 5-10% weight loss, and behavioral support; time-restricted eating (20-hour fast/4-hour eating window) improves beta-cell function and reduces HbA1c by 0.32%.
•Start metformin as first-line pharmacotherapy for most patients: 500 mg orally twice daily, titrated to 1000 mg twice daily as tolerated; hold if eGFR falls below 30 mL/min/1.73 m²; monitor for gastrointestinal side effects and consider extended-release formulation.
•In patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), initiate an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit independent of baseline HbA1c or metformin use, these agents now share first-line status per the ADA/EASD 2022 consensus.
•Prescribe empagliflozin 10 mg once daily (target 25 mg) or canagliflozin 100 mg once daily or dapagliflozin 10 mg once daily for SGLT2i; educate patients about euglycemic DKA risk and to hold the medication during acute illness or before elective surgery (at least 24 hours, 72 hours for on-pump CABG).
•Initiate liraglutide 0.6 mg subcutaneously daily for one week, then increase by 0.6 mg weekly to a target dose of 1.8 mg daily; alternatively, start semaglutide 0.25 mg subcutaneously weekly for four weeks, then escalate to 0.5 mg weekly, and if needed to 1.0 mg weekly for glycemic and cardiovascular benefit.
•For dual GIP/GLP-1 receptor agonism, use tirzepatide 2.5 mg subcutaneously weekly for four weeks, then escalate by 2.5 mg every four weeks to a maximum of 15 mg weekly, the most effective agent for HbA1c reduction (mean -1.96% vs placebo) and weight loss (-9.57 kg).
•If additional glucose lowering is needed without cardiorenal indication, add a DPP-4 inhibitor (sitagliptin 100 mg once daily, reduced to 50 mg if eGFR 30-50, 25 mg if <30) or basal insulin; avoid saxagliptin due to increased heart failure hospitalization (HR 1.27).
•Initiate basal insulin when HbA1c remains >9.0% on oral triple therapy or if catabolic symptoms (weight loss, polyuria) are present: start insulin glargine 10 units once daily, titrate by 10-15% weekly to achieve fasting glucose 4.0-5.5 mmol/L; insulin degludec provides non-inferior control with less nocturnal hypoglycemia.
•For hospitalized patients requiring insulin, use a basal-bolus regimen (glargine once daily plus glulisine three times daily before meals) rather than sliding-scale insulin, this reduces the composite of wound infection, pneumonia, and acute renal failure (8.6% vs 24.3%, OR 3.39).
•Target an HbA1c <7.0% for most nonpregnant adults; consider <6.5% for young patients (<40 years) with short disease duration and no CVD; target <8.0% for older patients with limited life expectancy or advanced complications; reassess every 3-6 months.
•Manage cardiovascular risk concurrently: prescribe a statin to achieve LDL <70 mg/dL (or <55 mg/dL in very high-risk patients); use ACE inhibitor or ARB for hypertension and albuminuria; target blood pressure <130/80 mm Hg, with caution for intensive targets <120 mm Hg (stroke benefit but increased serious adverse events, NNH=50).
•Avoid routine combination of fenofibrate with statin, the ACCORD lipid trial showed no cardiovascular benefit (HR 0.92) and potential harm in women; use fenofibrate as monotherapy only in severe hypertriglyceridemia (triglycerides >500 mg/dL).
•In diabetic ketoacidosis (glucose >250 mg/dL, pH <7.3, bicarbonate <15, positive ketones): administer 0.9% saline at 15-20 mL/kg/hour IV (max 1.5 L in first hour), give IV regular insulin 0.1 U/kg bolus followed by 0.1 U/kg/hour continuous infusion, and monitor potassium every 2 hours; when glucose falls below 200 mg/dL, reduce insulin infusion rate to 0.02-0.05 U/kg/hour.
•Transition from IV to subcutaneous insulin in DKA only after the anion gap normalizes (≤12 mmol/L) and the patient is tolerating oral intake; administer basal insulin (e.g., glargine 0.2-0.3 U/kg) 2 hours before stopping the IV insulin infusion to prevent rebound hyperglycemia.
•Refer for metabolic surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) in patients with BMI ≥35 kg/m² or BMI ≥30 kg/m² with poorly controlled T2DM, remission rates of 60-80% at 1-2 years with durability up to 10 years, superior to medical therapy.
•In pregnancy, use insulin as first-line therapy; continuing metformin is reasonable but monitor for small-for-gestational-age infants; target fasting glucose <95 mg/dL, 1-hour postprandial <140 mg/dL, and 2-hour <120 mg/dL.
•In youth-onset T2DM, start metformin 500 mg twice daily (max 2000 mg) plus intensive lifestyle; add a GLP-1 receptor agonist (dulaglutide 0.75 mg weekly, titrate to 1.5 mg) if HbA1c remains above target.
•Screen and treat depression (PHQ-9 annually), depression doubles as a risk factor and a complication of T2DM; treatment improves glycemic control and quality of life.
•For primary prevention of T2DM in prediabetes: recommend lifestyle intervention (reduces incidence by 43%); consider metformin 500 mg twice daily or pioglitazone 15-45 mg daily (off-label, NNT=18 over 2.4 years) in high-risk individuals with impaired glucose tolerance.
•What NOT to do: do not use saxagliptin in patients at risk for heart failure; do not target systolic BP <120 mm Hg in elderly or frail patients; do not use sliding-scale insulin in hospitalized patients who are eating; do not use fenofibrate as add-on to statin for cardiovascular prevention.

Board Review — High Yield

•UKPDS legacy effect, Early intensive glycemic control reduces long-term MI by 15% and all-cause mortality by 13% despite early loss of HbA1c differences.
•CREDENCE trial, Canagliflozin 100 mg daily reduces end-stage kidney disease by 32% (HR 0.68) in albuminuric CKD patients.
•LEADER trial, Liraglutide 1.8 mg daily reduces cardiovascular death by 22% (HR 0.78) in high-risk T2DM.
•Diabetic ketoacidosis (DKA), Glucose >250 mg/dL, pH <7.3, bicarbonate <15, positive ketones; treat with IV fluids, IV insulin 0.1 U/kg bolus + 0.1 U/kg/h, and potassium repletion.
•Hyperosmolar hyperglycemic state (HHS), Glucose >600 mg/dL, osmolality >320 mOsm/kg, pH >7.3; higher mortality than DKA (~15%).
•Metformin, Inhibits hepatic gluconeogenesis; first-line therapy; reduces MI by 33% in overweight UKPDS subgroup; contraindicated if eGFR <30.
•Incretin axis defect, Reduced GLP-1 secretion and impaired GIP action in T2DM lead to blunted glucose-stimulated insulin secretion and hyperglucagonemia.
•Screening in PCOS, OGTT is preferred over HbA1c because isolated fasting glucose misses ~33% of glucose intolerance.
•Age at diagnosis as risk stratifier, Each 1-year earlier diagnosis increases mortality risk by 4% and microvascular disease by 5%.
•Prediabetes prevention, Lifestyle intervention reduces T2DM incidence by 43% (RR 0.57); pioglitazone reduces conversion by 72% (HR 0.28; NNT=18).

Deep Dive — Evidence Details

Definition, Classification and Axis Nomenclature

▸T2DM is a heterogeneous syndrome best understood through data-driven subtypes (SAID, SIDD, SIRD, MOD, MARD) that improve prognostic stratification and guide therapy.
▸Prediabetes definitions vary by organization; HbA1c identifies fewer individuals than OGTT but those meeting both criteria have worse metabolic profiles [16].
▸Nomenclature matters: avoid 'non-insulin-dependent' and 'adult-onset' as they are clinically misleading.

HY High Yield: The Ahlqvist clusters (SAID, SIDD, SIRD, MOD, MARD) are actionable. SIRD carries highest cardiovascular risk; SIDD highest retinopathy risk; SAID often requires early insulin [4,19].

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder defined by hyperglycemia that results from a progressive decline in beta cell function superimposed on a background of insulin resistance. This is not a single disease but a heterogeneous syndrome with multiple subtypes that differ in pathophysiology, natural history, and risk of complications ^[18]^D5.

Also Called: non-insulin-dependent diabetes mellitus (NIDDM), adult-onset diabetes, maturity-onset diabetes. The terms "insulin-dependent" and "non-insulin-dependent" are no longer recommended by the ADA and WHO because they confuse the treatment requirement with the underlying pathology.

Definition of Key Terms:

(intermediate hyperglycemia): encompasses impaired fasting glucose (FPG 100-125 mg/dL or 5.6-6.9 mmol/L), impaired glucose tolerance (2-hour post-75g glucose 140-199 mg/dL or 7.8-11.0 mmol/L), and HbA1c 5.7-6.4% (39-47 mmol/mol). These categories identify individuals at high risk of progression to T2DM ^[26]^B2a.
Overt T2DM: FPG ≥126 mg/dL (7.0 mmol/L), 2-hour glucose ≥200 mg/dL (11.1 mmol/L), HbA1c ≥6.5% (48 mmol/mol), or random glucose ≥200 mg/dL in a symptomatic patient.

Classification of T2DM Subtypes: Data-driven clustering has identified five reproducible subgroups of diabetes that extend beyond the traditional type 1/type 2 dichotomy ^[4]^B2b^[19]^C4. These clusters differ in age at diagnosis, BMI, insulin sensitivity, and complication risk:

Subtype	Key Features	Clinical Implications
Severe autoimmune diabetes (SAID)	Autoantibody positive, early onset, low BMI, rapid beta cell failure	Often misclassified as T2DM; requires early insulin ^[4]^B2b
Severe insulin-deficient diabetes (SIDD)	No autoantibodies, low HOMA-B, early onset, low BMI	High risk of retinopathy and sarcopenia; insulin soon needed ^[4]^B2b^[19]^C4
Severe insulin-resistant diabetes (SIRD)	High HOMA-IR, high BMI, high TG	Highest risk of nephropathy, NAFLD; SGLT2i/GLP-1 RA preferred ^[4]^B2b
Mild obesity-related diabetes (MOD)	Obese, moderate insulin resistance	Most common in younger populations; weight loss is cornerstone
Mild age-related diabetes (MARD)	Older age, lower BMI, milder metabolic derangement	Slowest progression; often sufficient ^[19]^C4

This classification carries prognostic and therapeutic implications: SIRD and SIDD clusters have the highest cardiovascular risk, while SIDD and SAID are linked to sarcopenia ^[4]^B2b^[11]^B3b. Classification uncertainty can be quantified using normalized relative entropy, which when accounted for improves the ability of subtypes to predict 10-year CVD risk ^[19]^C4.

Nomenclature: This article refers to the disease as T2DM throughout. The term "non-insulin-dependent" is avoided because many patients eventually require insulin. "Adult-onset" is misleading given the rising incidence in children and adolescents ^[13]^D5.

Pearl: Up to 19-23% of youth with T2DM have comorbid depression, and assessment method significantly influences reported prevalence (clinical interview 12% vs self-report 25%) ^[25]^B2a. Always screen with validated diagnostic criteria, not just symptom scales.

Axis Physiology, Pathophysiology and Biochemical Signature

▸T2DM results from the parallel failure of insulin resistance, progressive beta-cell dysfunction, alpha-cell glucagon dysregulation, and an impaired incretin axis.
▸The biochemical signature includes elevated fasting insulin and C-peptide early (declining later), an elevated proinsulin-to-insulin ratio, inappropriately high glucagon, and a classic dyslipidemia (high triglycerides, low HDL).
▸Inflammatory cytokines, mitochondrial dysfunction, and gut microbiota alterations accelerate each step, explaining substantial inter-individual variability in disease progression.

Having defined the diagnostic criteria, attention now turns to the core axis physiology that underlies the disease. Type 2 diabetes mellitus (T2DM) arises from failure of the integrated glucose homeostatic system, a network that links pancreatic islet hormones, the entero-insular (incretin) axis, and insulin-sensitive tissues (liver, muscle, adipose) to maintain normoglycemia. The breakdown is not a single lesion but a cascade of parallel defects, each detectable early, each worsening over time, and each providing a therapeutic target.

The Pathophysiologic Chain: Five Linked Failures

(1) Insulin resistance as the initiating defect. In susceptible individuals, driven by overnutrition, physical inactivity, and genetic background (notably in South Asians, who develop T2DM at lower BMI and younger age ^[47]^D5), adipose tissue exceeds its storage capacity, promoting ectopic lipid accumulation in liver and muscle. This lipotoxic environment impairs insulin signaling via serine phosphorylation of IRS-1, reduced GLUT4 translocation, and activation of PKC isoforms ^[85]^D5. The resulting insulin resistance forces the beta-cell to hypersecrete insulin to maintain euglycemia, a state of compensated insulin resistance ^[85]^D5.

(2) Beta-cell dysfunction and progressive failure. The beta-cell cannot sustain compensatory hypersecretion indefinitely. Glucotoxicity directly impairs insulin gene transcription and triggers beta-cell apoptosis ^[42]^A1b^[91]^D5. Lipotoxicity, oxidative stress, and amyloid deposition further erode secretory capacity. Short-term intensive insulin therapy early in T2DM can partially restore beta-cell function (pooled increase in HOMA-B by 13% ^[55]^A1a), indicating that glucotoxicity is a modifiable driver. Over years, beta-cell mass declines by 30-60% relative to age-matched controls ^[55]^A1a^[61]^C4.

(3) Alpha-cell dysfunction and glucagon dysregulation. In T2DM, the alpha-cell becomes resistant to the suppressive effect of glucose and to paracrine insulin, leading to inappropriately elevated fasting and postprandial glucagon ^[71]^D5. This relative hyperglucagonemia drives hepatic glucose output, contributing to both fasting and postprandial hyperglycemia. The normal glucagon-suppressive effect of GLP-1 is also blunted ^[60]^D5^[71]^D5.

(4) Incretin axis defect. The postprandial secretion of glucagon-like peptide-1 (GLP-1) from enteroendocrine L-cells is substantially reduced in T2DM ^[60]^D5^[71]^D5^[89]^D5. This leads to diminished glucose-stimulated insulin secretion, reduced suppression of glucagon, and delayed satiety. Glucose-dependent insulinotropic polypeptide (GIP) secretion is normal, but its insulinotropic effect is impaired, possibly due to GIP receptor downregulation ^[60]^D5. The incretin defect amplifies both beta-cell and alpha-cell abnormalities.

(5) Inflammation, mitochondrial dysfunction, and the gut microbiota. Adipose tissue in obesity recruits macrophages and releases pro-inflammatory cytokines (TNF-α, IL-6) that propagate insulin resistance ^[87]^D5. Blockade of IL-1 with anakinra improved glycemia and C-peptide secretion, confirming a causal role for inflammation ^[42]^A1b. Skeletal muscle mitochondria in insulin-resistant individuals exhibit reduced oxidative capacity, promoting intramyocellular lipid accumulation ^[88]^D5. The gut microbiota in T2DM shows altered composition (reduced Firmicutes, increased Bacteroidetes) and reduced production of short-chain fatty acids that maintain gut barrier integrity ^[69]^D5^[90]^D5. Low-grade endotoxemia from a leaky gut further drives systemic inflammation ^[69]^D5. These modifiers explain substantial inter-individual variability in disease progression ^[56]^B2a^[57]^D5^[84]^D5.

Biochemical Signature

The hallmark laboratory pattern in established T2DM includes: fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) and/or HbA1c ≥ 6.5% (48 mmol/mol) ^[77]^A1c, with and low HDL-cholesterol as the classic dyslipidemia ^[78]^D5. The paired hormone profile early in the disease shows elevated fasting insulin and C-peptide (reflecting insulin resistance) with an elevated proinsulin-to-insulin ratio (a sensitive marker of beta-cell stress). As beta-cell function declines, insulin and C-peptide fall toward the normal range despite significant hyperglycemia. Glucagon is inappropriately elevated relative to glucose ^[71]^D5. Inflammatory markers (hs-CRP, IL-6, fibrinogen) are consistently higher, even after adjusting for adiposity ^[87]^D5. Plasma magnesium is reduced in approximately 30% of patients, correlating with higher triglycerides and glucose and lower insulin ^[70]^C4.

The combination of insulin resistance and beta-cell dysfunction in T2DM creates a self-reinforcing cycle: hyperglycemia worsens insulin resistance and beta-cell toxicity, which begets more hyperglycemia ^[91]^D5. Breaking this cycle, with lifestyle, insulin sensitizers, incretin-based therapies, or SGLT2 inhibitors, targets the axis at multiple nodes, restoring the balance between insulin demand and supply.

Pearl: A patient with early T2DM and an elevated proinsulin-to-insulin ratio plus elevated fasting glucagon has the classic triad of insulin resistance, beta-cell stress, and alpha-cell dysregulation, all three must be addressed, not just the glucose number.

Biochemical Signature of Type 2 Diabetes Mellitus

Parameter	Early/Compensated	Late/Decompensated	Mechanism
Fasting plasma glucose	≥7.0 mmol/L	≥7.0 mmol/L (often higher)	Hepatic glucose output due to insulin resistance + hyperglucagonemia
HbA1c	≥6.5% (48 mmol/mol)	≥8-10%	Cumulative glycemic exposure
Fasting insulin / C-peptide	Elevated	Normal to low	Insulin resistance → compensatory hypersecretion → eventual beta-cell failure
Proinsulin-to-insulin ratio	Elevated	Markedly elevated	Beta-cell stress and defective proinsulin processing
Glucagon (fasting)	Inappropriately normal or elevated	Elevated relative to glycemia	Alpha-cell resistance to glucose and insulin; impaired GLP-1 suppression
Triglycerides	Elevated	Elevated	Increased VLDL1 production and decreased catabolism ^[78]^D5
HDL cholesterol	Low	Low	Increased HDL catabolism ^[78]^D5
hs-CRP / IL-6	Elevated	Elevated	Adipose tissue inflammation and cytokine release ^[87]^D5
Magnesium	Decreased in ~30%	Decreased	Correlates with hypertriglyceridemia and hyperglycemia ^[70]^C4
Gut dysbiosis (Firmicutes:Bacteroidetes ratio)	Decreased	Decreased	Increased intestinal permeability, endotoxemia, reduced SCFA ^[69]^D5^[90]^D5

Epidemiology, Etiology and Risk Factors

▸Men account for ~17.7 million more T2DM cases globally but women have a greater risk factor burden at diagnosis.
▸Gestational diabetes confers a 3.5-fold increased risk of future T2DM, independent of interim glycemic status.
▸Physical inactivity is the most modifiable driver: 150 min/week of moderate activity reduces incident T2DM by 26%.

From the molecular pathways that drive insulin resistance and beta-cell dysfunction, the epidemiological picture emerges across populations with stark disparities. Globally, diabetes affects an estimated 537 million adults, with men accounting for ~17.7 million more cases than women ^[131]^D5. Prevalence is rising in both sexes, but men are typically diagnosed at a younger age and lower body fat mass, whereas women carry a greater burden of obesity and psychosocial risk factors at diagnosis ^[84]^D5^[131]^D5. South Asians develop T2DM at younger ages and substantially lower BMI than White Caucasian populations, implicating heightened insulin resistance as the predominant mechanism ^[47]^D5. In children and adolescents, the obesity-driven surge in T2DM is most dramatic in developing countries: childhood obesity prevalence now reaches 41.8% in Mexico, 22.1% in Brazil, and 22.0% in India ^[137]^D5.

Risk Factors

The risk of T2DM arises from a complex interplay of non-modifiable and modifiable factors. The metabolic syndrome, clustering abdominal obesity, insulin resistance, dyslipidemia, and , confers an approximate 5-fold increased risk for incident T2DM ^[85]^D5. Physical inactivity is among the most potent reversible drivers; achieving ≥150 min/week of moderate activity (11.25 MET-h/week) reduces risk by 26%, and doubling this dose yields a 36% reduction ^[123]^B2a. Depression, a bidirectional contributor, increases the risk of developing T2DM by 37% (RR 1.37, 95% CI 1.14-1.63) ^[124]^B2a. Among women, gestational diabetes carries an adjusted hazard ratio of 3.52 (95% CI 3.26-3.80) for subsequent T2DM ^[145]^B2b; early (OR 1.15) and premature ovarian insufficiency (OR 1.50) further elevate risk ^[115]^B2a. Long-term exposure to air pollutants is also significant: each 10 μg/m³ increment in PM2.5 raises risk by 39% (RR 1.39) ^[116]^B2a. Protective factors include moderate alcohol intake (J-shaped relationship in overweight/obese women only, with maximum 31% risk reduction at ~16 g/day) ^[104]^B2a and vitamin D supplementation ≥1000 IU/day in , which reduces progression by 12% (RR 0.88, 95% CI 0.79-0.99) ^[102]^A1a.

Risk Factor	Odds Ratio / Relative Risk (95% CI)	Evidence Level
Physical inactivity (vs ≥150 min/week)	RR 0.74 (0.69-0.80) for active ^[123]^B2a	1a
Depression	RR 1.37 (1.14-1.63) ^[124]^B2a	1a
Gestational diabetes (subsequent T2DM)	aHR 3.52 (3.26-3.80) ^[145]^B2b	2b
Early menopause (<45 yr)	OR 1.15 (1.04-1.26) ^[115]^B2a	2a
Premature ovarian insufficiency (<40 yr)	OR 1.50 (1.03-2.19) ^[115]^B2a	2a
PM2.5 (per 10 μg/m³)	RR 1.39 (1.14-1.68) ^[116]^B2a	2a
Metabolic syndrome	~5-fold increased risk ^[85]^D5	5
Vitamin D ≥1000 IU/day in prediabetes	RR 0.88 (0.79-0.99) ^[102]^A1a	1a
South Asian ethnicity	Higher risk at lower BMI ^[47]^D5	5

Temporal Trends

The global prevalence of T2DM has more than doubled over the past three decades, with the steepest rises in low- and middle-income countries ^[137]^D5. Urbanization, dietary Westernization, and declining physical activity are primary drivers. The onset of T2DM is shifting to younger ages, particularly in populations with high childhood obesity rates ^[57]^D5^[137]^D5.

Pearl: Screen for T2DM in any adult with metabolic syndrome, a history of gestational diabetes, or South Asian ancestry, even at normal BMI, and consider that depression doubles as both a risk factor and a complication, warranting bidirectional surveillance ^[124]^B2a.

Clinical Presentation

▸Post-prandial hyperglycemia occurs in 84% of patients, even when HbA1c is at goal
▸Checkpoint inhibitor-associated autoimmune diabetes presents with acute, severe hyperglycemia and low C-peptide, often without autoantibodies
▸Non-obese patients with high insulin requirements (>100 U/day) should be screened for lipodystrophy syndromes

HY High Yield: **Post-prandial hyperglycemia is the rule, not the exception:** 84% of patients with non-insulin-treated T2DM have at least one glucose spike >160 mg/dL after meals, even when HbA1c is <7.0% [159].

! Warning: **Checkpoint inhibitor-associated diabetes can present as DKA:** Median glucose at diagnosis is 32.5 mmol/L (585 mg/dL) with very low C-peptide; requires immediate insulin and does not resolve with immunotherapy cessation [147].

From asymptomatic hyperglycemia discovered on routine labs to fulminant diabetic ketoacidosis, the presentation of type 2 diabetes reflects its heterogeneous pathogenesis and the patient's underlying metabolic reserve. The classic triad of polyuria, polydipsia, and remains the most recognizable symptom complex, but many patients are identified incidentally during screening for other conditions. Post-prandial hyperglycemia is a particularly common and often underappreciated feature: among non-insulin-treated patients, 84% had at least one post-prandial glucose value >8.89 mmol/L (160 mg/dL) over a one-week period, and 81% had a glucose excursion ≥2.22 mmol/L (40 mg/dL), even among those with apparently good glycemic control ^[159]^B2c. Depression symptoms are also prevalent and associate with abdominal obesity and cardiovascular disease, independent of anxiety ^[160]^B2c.

Presenting Symptoms

The onset is typically insidious over weeks to months, though a subset of patients present acutely with metabolic decompensation. Checkpoint inhibitor-associated autoimmune diabetes (CIADM) is a distinct, rapidly progressive form: median time from immunotherapy initiation to diagnosis is 25 weeks (IQR 17.5-34.5), with a median presenting glucose of 32.5 mmol/L (585 mg/dL), median HbA1c 7.6%, and a median C-peptide of 0.35 nmol/L (normal ≥0.37), reflecting near-total β-cell failure ^[147]^C4. In contrast, elderly-onset type 2 diabetes (eT2DM) often presents with milder hyperglycemia, weight loss, and mild elevation of serum amylase due to underlying pancreas atrophy and islet amyloid deposition ^[149]^B3b.

Sex-specific differences in presentation are clinically important. Men are typically diagnosed at a younger age and lower BMI, while women bear a greater burden of obesity and psychosocial stress at diagnosis ^[131]^D5. Women also have a higher relative risk of cardiovascular disease and mortality compared with men of similar glycemic status ^[84]^D5.

Neurological Examination Findings

is the most common neurological complication. The classic pattern is a symmetric, length-dependent sensorimotor polyneuropathy: patients report numbness, tingling, and a "stocking-glove" distribution of sensory loss. On examination, light-touch and vibratory sensation are reduced in the toes and feet, and ankle reflexes are diminished or absent ^[154]^C4. (DPN) is also associated with altered intrinsic brain activity: resting-state fMRI shows decreased amplitude of low-frequency fluctuations in prefrontal and orbitofrontal cortices, which correlate with higher Toronto Clinical Scoring System scores and slower gait speed ^[148]^B3b. may present with resting tachycardia, orthostatic hypotension, , or .

Phenotypic Variants

A growing appreciation for the heterogeneity of type 2 diabetes has led to the recognition of several distinct phenotypic variants, each with implications for :

Variant	Key Features	Frequency
Elderly-onset T2DM (eT2DM)	Pancreas atrophy (50% lower weight), islet amyloid deposition, mild serum amylase elevation, no clinical pancreatitis ^[149]^B3b	Common in older populations
Renal glycosuria	Younger age, lower BMI, lower HOMA-IR, less ; associated with SLC5A2 (V359G) or HNF1A (R131W) mutations ^[150]^B3b	~3% of Chinese T2DM cohort
Early-onset T2DM in Indians	42% normal BMI, low islet autoimmunity (3% GADA), infrequent MODY/mitochondrial mutations ^[152]^B3b	Common in South Asian populations
Familial partial (FPLD)	Non-obese (BMI ≤27 kg/m²), insulin requirement >100 U/day, features of lipodystrophy; associated with LMNA or PPARG mutations (including novel Y151C) ^[161]^C4	Rare, but underdiagnosed
Checkpoint inhibitor-associated autoimmune diabetes (CIADM)	Acute onset after anti-PD-1 therapy, low C-peptide, often DAA-negative, permanent insulin dependence ^[147]^C4	1.9% of metastatic patients on anti-PD-1
GCK-MODY	Mild fasting hyperglycemia, non-progressive, may coexist with insulin resistance and obesity ^[168]^C4	Rare in T2DM cohorts

Red Flags

Certain presentations require urgent evaluation. New-onset diabetes with glucose >25 mmol/L, low C-peptide, and recent immunotherapy exposure signals CIADM, which requires immediate insulin therapy ^[147]^C4. Unexplained fever, neurological deficits, or skin infections in a patient with poorly controlled diabetes should raise suspicion for disseminated MRSA or nontuberculous mycobacterial infection, as minor wounds (e.g., moxibustion burns, injection sites) can serve as portals for bloodstream dissemination ^[166]^C4^[167]^C4. Insulin requirements >100 U/day in a non-obese patient should prompt evaluation for lipodystrophy syndromes ^[161]^C4.

Atypical Presentations

Depression may be the presenting complaint in patients with type 2 diabetes, particularly when accompanied by abdominal obesity and cardiovascular disease ^[160]^B2c. Post-prandial hyperglycemia can occur even in patients with normal fasting glucose and HbA1c <7.0%, making self-monitored glucose profiles essential for diagnosis ^[159]^B2c. Transient positivity for glutamic acid decarboxylase antibodies (GADA) does not rule out monogenic diabetes; it may reflect metabolic stress rather than autoimmune disease ^[168]^C4. Subclinical hypercortisolism (Cushing syndrome) should be considered in patients with difficult-to-control diabetes, hypertension, and osteoporosis, especially when late-night salivary cortisol and low-dose suppression testing are abnormal ^[156]^B2b.

Pearl: In a non-obese patient with type 2 diabetes requiring >100 U of insulin per day, consider familial partial lipodystrophy, screening with clinical examination for lipodystrophy, lipid profile, and genetic testing for LMNA and PPARG mutations can identify a treatable subtype ^[161]^C4.

Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization

▸The 75-g OGTT with 2-hour plasma glucose ≥11.1 mmol/L is the diagnostic gold standard, particularly for prediabetes and high-risk populations.
▸HbA1c ≥6.5% is the preferred first-line screening test but can be falsely low in anemia, hemoglobinopathy, and chronic kidney disease.
▸Dynamic testing with OGTT is essential in post-gestational diabetes, PCOS, and when HbA1c/FPG are borderline.

Dx Diagnostic Essentials: The 75-g oral glucose tolerance test with 2-hour plasma glucose ≥11.1 mmol/L remains the diagnostic gold standard for type 2 diabetes [172].

HY High Yield: HbA1c may be falsely low in hemolytic anemia, hemoglobinopathies, and chronic kidney disease; use fasting glucose or OGTT in these settings.

Once clinical suspicion arises, whether from classic symptoms of polyuria, polydipsia, and weight loss or from risk factor screening, the diagnosis of type 2 diabetes is established through glycemic testing. The 75-g oral glucose tolerance test (OGTT) with a 2-hour plasma glucose ≥11.1 mmol/L remains the diagnostic gold standard ^[172]^A1b, though simpler tests suffice for most patients.

Establishing the Diagnosis

Four tests are accepted by current guidelines:

Test	Diagnostic Threshold	Notes
Fasting plasma glucose (FPG)	≥126 mg/dL (7.0 mmol/L)	After ≥8 h of no caloric intake
2-hour plasma glucose during 75-g OGTT	≥200 mg/dL (11.1 mmol/L)	Gold standard for equivocal cases
Hemoglobin A1c (HbA1c)	≥6.5% (48 mmol/mol)	First-line, convenient
Random plasma glucose with symptoms	≥200 mg/dL (11.1 mmol/L)	Confirms diagnosis without repeat

Confirmatory testing is required unless the patient presents with unequivocal hyperglycemia (random glucose ≥200 mg/dL plus classic symptoms). When HbA1c or FPG is borderline, the OGTT is particularly valuable and is the test of choice in high-risk populations.

Dynamic Testing: The Oral Glucose Tolerance Test

The OGTT provides a dynamic assessment of glucose handling. Its indications include:

Equivocal HbA1c or FPG: HbA1c 5.7-6.4% or FPG 100-125 mg/dL ( ).
Polycystic ovary syndrome (PCOS): OGTT is recommended because these women have higher insulin resistance and T2DM risk independent of obesity ^[196]^D5; incretin disturbances (higher GIP, lower late-phase GLP-1) may be early markers ^[197]^B3b.
: T2DM and metabolic syndrome are significantly more frequent than in matched controls ^[200]^B3b.

A novel predictor is the 1-hour postload glucose. A value ≥155 mg/dL (8.6 mmol/L) during the OGTT identifies individuals with normal glucose tolerance who are at increased risk for future T2DM and cardiovascular disease ^[186]^D5.

Limitations: The OGTT has questionable reproducibility, and its high sensitivity for impaired glucose tolerance comes at the expense of relatively low specificity ^[196]^D5.

Additional Biochemical Assessment

Insulin and C-peptide may be measured to differentiate diabetes type when needed. In established T2DM, C-peptide is generally normal or elevated; a low C-peptide in the setting of hyperglycemia suggests autoimmune or insulin-deficient diabetes (type 1 or latent autoimmune diabetes).

Insulin resistance scores can quantify metabolic risk. The metabolic score for insulin resistance (METS-IR), calculated as (Ln((2 × fasting glucose) + fasting triglycerides) × BMI) / (Ln(HDL-C)), correlates well with euglycemic-hyperinsulinemic clamp results. Subjects in the highest quartile (>50.39) had a 3.91-fold increased risk of incident T2DM (HR 3.91) ^[195]^B2b.

Other biomarkers under investigation include urinary zinc (higher levels associated with T2DM incidence; HR 1.21, 95% CI 1.08-1.36 in the Strong Heart Study) ^[189]^B2b, circulating myonectin ^[187]^C4, and bile acid profiles ^[185]^D5, but none are yet recommended for routine diagnosis.

Screening in Special Populations

Post-gestational diabetes: Reminder systems (to the woman, the physician, or both) increase postpartum OGTT uptake from 14% to 57% (RR 4.23, 95% CI 1.85-9.71) ^[212]^A1a. Even without progression to T2DM, women with prior GDM have a 2-fold higher risk of cardiovascular events (RR 1.98, 95% CI 1.57-2.50) and a 56% increased risk even if they never develop T2DM ^[122]^B2a.
PCOS: OGTT is recommended at diagnosis and during follow-up, especially in women with obesity or previous GDM ^[196]^D5. Amenorrhea is associated with more severe insulin resistance ^[199]^B2c.
Primary aldosteronism: T2DM prevalence is 17.2% vs. 10.4% in matched controls ^[200]^B3b.
: Screening should start at a younger age given the earlier peak incidence ^[178]^B2b.

Role of Imaging

Imaging is not used to diagnose T2DM. However, certain findings on routine abdominal CT or ultrasound may raise suspicion. Pancreatic triacylglycerol content, quantified by MRI, is specifically elevated in T2DM and decreases after weight loss with recovery of first-phase insulin secretion ^[192]^B2b. The pooled prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in Indian adults with T2DM is 56.9% ^[215]^C4; a liver ultrasound or transient elastography is indicated when liver disease is suspected. Novel CT-based quantification of pancreatic perivascular adipose tissue (PVAT) shows promise as an imaging biomarker for T2DM and its risk ^[217]^B3b.

Diagnostic Algorithm

Initial assessment: Measure HbA1c or FPG in adults aged ≥45 years, or younger with BMI ≥25 kg/m² plus one additional risk factor (e.g., family history, , GDM history, PCOS).
If HbA1c ≥6.5% or FPG ≥126 mg/dL: Repeat the same test on a different day to confirm, unless random glucose ≥200 mg/dL with symptoms.
If borderline (HbA1c 5.7-6.4% or FPG 100-125 mg/dL): Perform a 75-g OGTT. A 2-hour glucose ≥11.1 mmol/L confirms diabetes; a 1-hour glucose ≥155 mg/dL (8.6 mmol/L) identifies high-risk individuals ^[186]^D5.
When HbA1c is unreliable (anemia, hemoglobinopathy, chronic kidney disease, pregnancy, recent blood transfusion): Use FPG or OGTT as the primary diagnostic test.

Pearl: The 1-hour postload glucose ≥155 mg/dL during an OGTT identifies high-risk individuals even before HbA1c becomes abnormal; consider it in patients with strong family history or prior GDM ^[186]^D5.

Controversies and Guideline Disagreement

Question	Position A (ADA/EASD)	Position B (alternative)	Strength	Implication
Preferred initial test	HbA1c is first-line for screening	Some guidelines (e.g., WHO) still endorse FPG or OGTT as the gold standard	1C	HbA1c is convenient but misses some cases; OGTT should be used when HbA1c is equivocal or unreliable ^[196]^D5
Role of 1-hour PG	Not currently recommended by ADA for diagnosis	European studies support it for risk stratification	Lower	May identify high-risk NGT individuals earlier ^[186]^D5
Screening in PCOS	OGTT only in high-risk women (obesity, GDM history)	Some suggest OGTT in all PCOS	Weak	Data limited; risk of overdiagnosis ^[196]^D5

Severity, Staging and Risk Stratification

▸Age at diagnosis is the strongest independent risk factor for complications: each 1-year increase reduces mortality risk by 4% [183].
▸The WATCH-DM score (BMI, age, hypertension, creatinine, HDL-C, fasting glucose, QRS duration, MI, CABG) stratifies 5-year heart failure risk from 1.1% to 17.4% [226].
▸Insulin requirement identifies a high-risk subset with a hazard ratio of 3.29 for MACE [225] and a 46% prevalence of obstructive CAD [225].

HY High Yield: The WATCH-DM score is the only validated tool for HF risk specifically in T2DM, a score ≥14 places a patient in the highest quintile (17.4% 5-year HF risk), meriting early SGLT2 inhibitor initiation [226].

Once the diagnosis of type 2 diabetes is confirmed, the clinician must immediately stratify the patient's risk for complications to guide treatment intensity, glycemic targets, and surveillance intervals. This stratification is not a single staging system but a multidimensional assessment integrating clinical, laboratory, and imaging-derived factors.

Age at Diagnosis as a Dominant Risk Driver

Younger age at diagnosis is the strongest independent predictor of future complications. A meta-analysis of 26 studies (1,325,493 individuals) found that each 1‑year increase in age at diagnosis reduces the risk of all‑cause mortality by 4%, macrovascular disease by 3%, and microvascular disease by 5%, adjusted for current age ^[183]^B2a. A patient diagnosed at age 40, for example, carries a substantially higher lifetime risk than one diagnosed at age 60, even with identical HbA1c. This inverse association mandates earlier and more aggressive treatment in younger-onset disease.

Cardiovascular Risk Scores

Several validated scores refine cardiovascular risk prediction in T2DM. The WATCH-DM risk score, derived from the ACCORD trial using machine learning (random survival forest), integrates Weight (BMI), Age, , Creatinine, HDL‑C, fasting glucose, QRS duration, MI, and ^[226]^B2b. Each 1‑point increment in the score is associated with a 24% higher relative risk of heart failure hospitalization within 5 years. The cumulative 5‑year incidence of HF rises in a graded fashion from 1.1% in quintile 1 (score ≤7) to 17.4% in quintile 5 (score ≥14) ^[226]^B2b. The score performed well in external validation (C‑index 0.70, acceptable calibration) ^[226]^B2b.

The Metabolic Syndrome Severity Z score (MetS‑Z) tracks risk during treatment. In the Diabetes Prevention Program, a 1‑SD increase in 1‑year change in MetS‑Z was associated with a hazard ratio of 1.80 for incident T2DM within 1‑5 years, and the effect of lifestyle modification on T2DM risk was mediated by MetS‑Z changes ^[218]^B2b.

Insulin Requirement and Disease Burden

Patients with T2DM who require insulin therapy represent a higher‑risk subset. In a coronary CTA registry of 1,118 patients, the prevalence of obstructive CAD rose stepwise from 15% in those without diabetes and <3 cardiometabolic risk factors to 46% in insulin‑requiring T2DM ^[225]^B2b. Insulin use conferred the highest adjusted hazard of MACE (HR 3.29, 95% CI 1.28‑8.45) ^[225]^B2b.

Clustering and Subphenotypes

Data‑driven clustering of T2DM identifies distinct subtypes with different risk profiles. In a Japanese cohort, the severe autoimmune diabetes (SAID) and severe insulin‑deficient diabetes (SIDD) clusters were at highest risk for developing sarcopenia over 3 years ^[4]^B2b. Classification uncertainty, quantified by the normalized relative entropy (NRE), varies across subtypes; accounting for it improves the ability of subtypes to predict 10‑year CVD risk (R² increases from 17.4% to 31.5%) ^[19]^C4.

Fasting C‑Peptide Index and Vascular Phenotypes

A higher baseline fasting C‑peptide index (F‑CPI) is independently associated with a 77% lower odds of combined vascular phenotype (OR 0.23, P<0.001) over a median 3.85 years ^[236]^B2b. Visceral obesity significantly attenuates this protective effect (P interaction <0.05) ^[236]^B2b. Monitoring F‑CPI trajectories may refine risk stratification for micro‑ and macrovascular complications.

Organ‑Specific Risk Stratification

Liver: In patients with T2DM and NAFLD, the adipose tissue insulin resistance index (Adipo‑IR) is the strongest independent predictor of advanced fibrosis (OR 1.51, P=0.03), surpassing BMI and steatosis ^[221]^C4. Screening for NASH is recommended because the presence of NASH worsens hyperinsulinemia, dyslipidemia, and adipose/hepatic insulin resistance ^[223]^C4^[224]^B3b.

Brain: A cognitive risk stratification score (RSS) incorporating MoCA, diastolic blood pressure, and Short Physical Performance Battery yields an AUC of 0.802 for detecting cognitive impairment; at an optimal cutoff of 0.3, sensitivity is 63.5% and specificity 86.8% ^[219]^C4.

Kidney: Elevated urinary ACE2 concentration is independently associated with T2DM (OR 1.80) and is highly predictive of microalbuminuria (OR 2.68) ^[227]^C4.

Integration Into Clinical Practice

Risk stratification is not a one‑time event. The presence of NAFLD, insulin requirement, young age at diagnosis, or a high WATCH‑DM score should trigger lower glycemic targets (e.g., HbA1c <6.5% if safely achievable) and earlier initiation of agents with proven cardiovascular benefit (SGLT2 inhibitors, GLP‑1 receptor agonists). Conversely, older patients with few comorbidities and a low risk score may reasonably be treated to a HbA1c of <8.0%. The 2021 Philippine CPG strongly recommends screening for T2DM using fasting blood sugar, but once diagnosed, stratification of risk is the foundation of personalized care ^[238]^A1c^[164]^A1c.

Pearl: Age at diagnosis is the single most powerful risk stratifier in T2DM, a patient diagnosed before age 40 has a 4% higher per‑year risk of mortality than a patient diagnosed at age 60, and should be managed with the same intensity as a patient with established cardiovascular disease ^[183]^B2a.

Key Risk Stratification Tools in Type 2 Diabetes

Tool	Components	Outcome Predicted	Performance
WATCH-DM score ^[226]^B2b	BMI, Age, hypertension, Creatinine, HDL-C, FPG, QRS duration, MI, CABG	5-year HF hospitalization	C-index 0.70; 5-year HF risk 1.1% (quintile 1) to 17.4% (quintile 5)
MetS-Z score ^[218]^B2b	Waist circumference, glucose, BP, triglycerides, HDL-C	Incident T2DM, CVD	HR 1.80 per 1-SD change in MetS-Z for T2DM
Cognitive RSS ^[219]^C4	MoCA, DBP, Short Physical Performance Battery	Cognitive impairment	AUC 0.802; sensitivity 63.5%, specificity 86.8% at cutoff 0.3
F-CPI ^[236]^B2b	Fasting C-peptide / glucose	Combined vascular phenotype	OR 0.23 for high baseline F-CPI (P<0.001)
Adipo-IR ^[221]^C4	Fasting FFA × fasting insulin	Advanced liver fibrosis (F≥2)	OR 1.51 (P=0.03) independent of BMI, steatosis

Acute Management and Endocrine Emergencies

▸DKA incidence is rising in T2DM, partly driven by SGLT2i use which increases ketone production and risk of euglycemic DKA.
▸Basal-bolus insulin is superior to sliding-scale in hospitalized T2DM patients, reducing postoperative complications (OR 3.39).
▸SGLT2i should be held 24-72 hours before surgery or during acute illness; empagliflozin before CABG reduced AKI (RR 0.57) without increasing DKA.

! Warning: Euglycemic DKA (glucose <200 mg/dL) is frequently missed. Check serum ketones and anion gap in any SGLT2i-treated patient with nausea, vomiting, or metabolic acidosis [245] [258].

Once severity and risk stratification have been established, a subset of patients with type 2 diabetes mellitus (T2DM) present with acute metabolic decompensations, diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). Although DKA is classically associated with type 1 diabetes, hospital admission for DKA in adults with T2DM in England increased 4.24% annually between 1998 and 2013, driven by insulinopenia, intercurrent illness, and use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) that promote ketogenesis ^[252]^B3b ^[245]^A1b ^[258]^B3b. HHS, characterized by extreme hyperglycemia >600 mg/dL and serum osmolality >320 mOsm/kg without significant ketosis, carries higher mortality than DKA and demands equally aggressive volume repletion.

Step 1: Diagnosis and Severity Classification

Diagnose DKA when glucose >250 mg/dL, pH <7.3, bicarbonate <15 mEq/L, and positive serum or urine ketones. Classify as mild (pH 7.25-7.30), moderate (pH 7.00-7.24), or severe (pH <7.00). For HHS, key criteria: glucose >600 mg/dL, effective osmolality >320 mOsm/kg, pH >7.30, bicarbonate >18. Euglycemic DKA (glucose <200 mg/dL) is increasingly recognized, particularly in patients on SGLT2i presenting with nausea, vomiting, or illness; check ketones and anion gap regardless of glucose level, because the metabolic basis, increased lipid oxidation and glucagon-to-insulin ratio, may elevate ketones without marked hyperglycemia ^[245]^A1b ^[258]^B3b.

Admit all DKA and HHS patients: those with severe DKA or altered mental status to the intensive care unit; mild-moderate DKA to a monitored medical ward capable of 1-2 h glucose and electrolyte checks.

Step 2: Fluid Resuscitation

Initiate isotonic 0.9% saline at 15-20 mL/kg per hour (max 1.5 L in the first hour for most adults), then 250-500 mL/h with transition to 0.45% saline if corrected sodium is normal or elevated. The goal is to replace half of the estimated deficit (6-8 L total in DKA, 8-12 L in HHS) within the first 12 hours. In HHS, free-water replacement is paramount and often requires higher volumes. Do not defer fluids for insulin administration; volume expansion alone can lower glucose significantly.

Step 3: Insulin Therapy

Begin intravenous regular insulin 0.1 U/kg bolus followed by 0.1 U/kg/h continuous infusion (U/kg/h without bolus). Lower the infusion rate to 0.02-0.05 U/kg/h once glucose falls below 200 mg/dL (DKA) or 300 mg/dL (HHS), while continuing the same rate to clear ketones. For HHS, the glucose target before reducing insulin is higher to avoid rapid osmotic shifts and cerebral edema. In the general surgical patient with T2DM, a basal-bolus regimen (glargine once daily plus glulisine before meals) achieved a mean daily glucose of 145±32 mg/dL versus 172±47 mg/dL with sliding-scale insulin and reduced a composite of wound infection, pneumonia, and acute renal failure (8.6% vs 24.3%; OR 3.39) ^[243]^A1b. This strategy is preferred over sliding-scale for hospitalized patients with T2DM who are eating.

Step 4: Potassium and Electrolyte Monitoring

Monitor serum potassium every 2 hours. If K+ <5.5 mEq/L, add 20-30 mEq per liter of IV fluid. If K+ <3.5 mEq/L, hold insulin and replete before starting insulin. Bicarbonate therapy is not recommended for pH ≥6.9; for pH <6.9, consider 50-100 mEq of NaHCO₃ in 200 mL over 30 minutes only after expert consultation because evidence of benefit is lacking. Phosphate replacement is considered only if levels fall below 1.0 mg/dL.

Step 5: Transition to Subcutaneous Insulin

Once the anion gap normalizes (≤12 mEq/L), glucose is stable, and the patient tolerates oral intake, transition to subcutaneous insulin. Administer basal insulin (e.g., glargine 0.2-0.3 U/kg) 2 hours before stopping the IV infusion, with rapid-acting insulin before meals. Failure to overlap appropriately leads to rebound hyperglycemia.

Special Considerations

SGLT2i and euglycemic DKA: SGLT2i raise plasma ketones through enhanced fatty acid oxidation and glucagon secretion ^[245]^A1b; they are associated with an increased risk of DKA (HR 1.78, 95% CI 1.44-2.19) ^[258]^B3b. Hold SGLT2i at least 24 hours before elective surgery or during acute illness. For perioperative protection, preoperative 25 mg daily (held 72 h before on-pump ) reduced postoperative acute kidney injury from 39.1% to 22.5% (RR 0.57, 95% CI 0.34-0.96) without increased ketoacidosis ^[100]^A1b. Euglycemic DKA should be considered in any patient on SGLT2i with unexplained acidosis ^[79]^A1a.

Parameter	DKA	HHS
Glucose	>250 mg/dL	>600 mg/dL
pH	<7.30	>7.30
Bicarbonate	<15 mEq/L	>18 mEq/L
Serum osmolality	Variable	>320 mOsm/kg
Ketones	Positive	Mild or absent
Typical fluid deficit	6-8 L	8-12 L
Key mortality risk	<5% overall	~15%

Pearl: In any patient with T2DM on an SGLT2i who presents with nausea, vomiting, or unexplained acidosis, measure ketones and the anion gap even if glucose is normal, euglycemic DKA is a treatable emergency that is missed when hyperglycemia is absent ^[245]^A1b ^[258]^B3b.

Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)

▸Long-term glycemic targets should be individualized: default HbA1c <7.0%, but more stringent (<6.5%) in young, healthy patients and less stringent (<8.0%) in those with advanced complications or limited life expectancy.
▸In patients with established ASCVD, CKD, or HF, SGLT2 inhibitors and GLP-1 receptor agonists should be initiated early, independent of metformin, to reduce cardiovascular events and slow kidney disease progression.
▸Metabolic surgery provides durable glycemic remission in eligible patients and should be considered as a definitive treatment option for those with BMI ≥35 kg/m² (or ≥30 kg/m² with poor control).

Rx Drug of Choice: First-line: Metformin 500 mg twice daily, titrated to 1000 mg twice daily, unless cardiorenal disease is present, in which case initiate an SGLT2i (e.g., empagliflozin 10 mg daily) or GLP-1 RA (e.g., liraglutide 1.8 mg daily) [77, 76, 107].

! Warning: Do not initiate saxagliptin in patients with heart failure or at risk for heart failure; it increased hospitalization for HF by 27% (HR 1.27, 95% CI 1.07-1.51) [251].

Once acute hyperglycemic crises are resolved and the patient is stable, the focus shifts to long-term treat-to-target strategies that reduce microvascular and macrovascular risk. The ADA/EASD 2022 consensus report recommends a patient-centered approach to glycemic targets, with the default goal of an HbA1c <7.0% for most nonpregnant adults ^[77]^A1c. More stringent targets (e.g., <6.5%) may be appropriate for younger patients with short disease duration and no cardiovascular disease, whereas less stringent targets (e.g., <8.0%) are reasonable for those with long-standing diabetes, limited life expectancy, or advanced complications ^[77]^A1c (1c). Blood pressure targets per ACCORD and ADVANCE: systolic <140 mm Hg (standard) or <120 mm Hg (intensive, with caution; ACCORD showed no primary composite benefit but stroke reduction: HR 0.59, 95% CI 0.39-0.89; NNT to prevent one stroke over 4.7 years = 476) ^[277]^A1b^[280]^A1b (1b). LDL target <70 mg/dL or <55 mg/dL in very high risk; the ACCORD lipid trial showed that adding fenofibrate to did not reduce cardiovascular events (HR 0.92, 95% CI 0.79-1.08) ^[278]^A1b (1b).

Step 1: Lifestyle Intervention as Foundation

Intensive lifestyle modification, dietary counseling, 150 min/week of moderate-to-vigorous physical activity, and behavioral support, remains the cornerstone of long-term . The Early ACTID trial demonstrated that an intensive diet intervention soon after diagnosis improved HbA1c by -0.28% (95% CI -0.46 to -0.10) at 6 months ^[179]^A1b (1b). Time-restricted eating (20 h fasting/4 h eating) for 6 weeks increased β-cell function (ISSI-2 +14%, P=0.03) and reduced HbA1c by -0.32% (P<0.001) in overweight patients with early T2DM ^[171]^A1b (1b). Meal replacement with caloric restriction further reduced HbA1c by -0.46% (95% CI -0.64 to -0.28) and body weight by -2.43 kg, with total meal replacement superior to partial ^[101]^A1a (1a). The Cochrane review of diet plus physical activity versus standard care in reported a 43% reduction in T2DM incidence (RR 0.57, 95% CI 0.50-0.64) over 2-6 years ^[27]^A1a (1a).

Step 2: First-Line Pharmacotherapy,

Metformin is the recommended first-line agent for most patients due to its efficacy, weight neutrality, low cost, and favorable safety profile ^[76]^D5 (5). The UKPDS 10-year follow-up showed that overweight patients initially randomized to metformin had persistent risk reductions for myocardial infarction (33%, P=0.005) and all-cause mortality (27%, P=0.002) despite early loss of glycemic differences ^[276]^A1b (1b). Starting dose: 500 mg twice daily, titrated to 1000 mg twice daily as tolerated [label]. Contraindicated when eGFR <30 mL/min/1.73 m². In patients with cardiorenal disease, the ADA/EASD 2022 consensus recommends considering SGLT2i or GLP-1 RA as first-line, independent of metformin, to reduce cardiovascular and kidney outcomes ^[77]^A1c (1c).

Figure 1: Management algorithm for long-term glycemic control (adapted from ADA/EASD 2022 consensus ^[77]^A1c).

Step 3: Add-On Therapy with Cardiorenal Benefit

In patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), the ADA/EASD 2022 consensus recommends an SGLT2i or GLP-1 RA with demonstrated cardiovascular benefit, independent of baseline HbA1c or metformin use ^[77]^A1c (1c).

SGLT2 inhibitors reduce heart failure hospitalizations and slow CKD progression. CREDENCE ( 100 mg daily) reduced the primary composite (end-stage kidney disease, doubling of creatinine, or renal/cardiovascular death) by 30% (HR 0.70, 95% CI 0.59-0.82; NNT = 56 over 2.62 years) ^[275]^A1b (1b). 25 mg daily before on-pump reduced postoperative AKI by 43% (RR 0.57, 95% CI 0.34-0.96) ^[100]^A1b (1b). 10 mg daily improved CIMT compared with metformin (between-group difference -0.058 mm, 95% CI -0.106 to -0.010) ^[285]^A1b (1b). A network meta-analysis of SGLT2i in T2DM confirmed reduced HHF across all agents, with empagliflozin showing an exploratory signal for lower ventricular arrhythmia risk (OR 0.31, 95% CI 0.11-0.86) ^[79]^A1a (1a).

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and mortality. LEADER ( 1.8 mg daily) reduced the primary MACE composite by 13% (HR 0.87, 95% CI 0.78-0.97) and cardiovascular death by 22% (HR 0.78, 95% CI 0.66-0.93; NNT = 77 over 3.8 years) ^[107]^A1b (1b). In patients with T2DM and peripheral artery disease, GLP-1 RA use was associated with a 27% lower risk of major limb events (RR 0.73, 95% CI 0.65-0.82) ^[80]^B2a (2a). (dual GIP/GLP-1 RA) at 15 mg weekly is the most effective agent for glycemic reduction (HbA1c - vs placebo) and weight loss (-9.57 kg), with a network meta-analysis showing superiority over 1.0 mg ^[48]^A1a (1a).

Drug class	Agent	Starting dose	Target/max dose	Renal adjustment	Key evidence (HR)	NNT (time)
SGLT2i	Canagliflozin	100 mg daily	100 mg daily	Avoid if eGFR <30	CREDENCE: primary outcome 0.70 (0.59-0.82) ^[275]^A1b	56 (2.62 yr)
SGLT2i	Dapagliflozin	10 mg daily	10 mg daily	Avoid if eGFR <25	CIMT reduction -0.058 mm ^[285]^A1b	Not calculable
SGLT2i	Empagliflozin	10 mg daily	25 mg daily	eGFR ≥20: continue	POST-CABG: AKI RR 0.57 (0.34-0.96) ^[100]^A1b	6 (per AKI event)
GLP-1 RA	Liraglutide	0.6 mg daily	1.8 mg daily	No adjustment	LEADER: CV death 0.78 (0.66-0.93) ^[107]^A1b	77 (3.8 yr)
GLP-1 RA	Semaglutide	0.25 mg weekly	1.0 mg weekly	No adjustment	NMA: HbA1c -1.39% vs placebo	Not calculable
Dual GIP/GLP-1 RA	Tirzepatide	2.5 mg weekly	15 mg weekly	No adjustment	NMA: HbA1c -1.96% vs placebo ^[48]^A1a	Not calculable
DPP-4i	Sitagliptin	100 mg daily	100 mg daily	eGFR <50: 50 mg	SAVOR- : MACE 1.00 (0.89-1.12) ^[251]^A1b	No benefit

Step 4: Intensification with Additional Agents

If HbA1c remains above target despite metformin and an SGLT2i/GLP-1 RA, consider adding a DPP-4 inhibitor, thiazolidinedione (pioglitazone), sulfonylurea, or basal insulin. The ADA/EASD consensus recommends a stepwise approach, with preference for agents that do not increase weight or hypoglycemia risk ^[77]^A1c (1c). Basal insulin (e.g., ) is effective when HbA1c >9.0% or if catabolic symptoms are present. The EASIE trial showed glargine (titrated to fasting glucose 4.0-5.5 mmol/L) reduced HbA1c by -1.72% vs -1.13% for sitagliptin (difference -0.59%, 95% CI -0.77 to -0.42) ^[180]^A1b (1b). Insulin degludec offers non-inferior glycemic control with lower nocturnal hypoglycemia (rate ratio 0.75, 95% CI 0.58-0.99) versus glargine ^[282]^A1b (1b).

Step 5: Definitive Therapy, Metabolic Surgery

For patients with T2DM and BMI ≥35 kg/m² (or ≥30 kg/m² if poorly controlled), metabolic surgery (Roux-en-Y gastric bypass, sleeve ) produces superior glycemic remission compared with medical therapy. A meta-analysis of 11 RCTs showed T2DM remission rates of 60-80% at 1-2 years, with durability up to 10 years ^[105]^D5 (1a). The benefits are similar in patients with BMI <35 kg/m², supporting expanded indications ^[105]^D5 (1a). Surgery improves cardiovascular risk factors and reduces long-term mortality, but requires lifelong nutritional monitoring.

Treatment Failure Protocol

Failure to achieve HbA1c target after 3-6 months of dual therapy warrants addition of a third agent or insulin. If HbA1c >9.0% or >10.0% with symptoms, initiate insulin immediately. The RABBIT 2 Surgery trial demonstrated that basal-bolus insulin (glargine once daily + glulisine before meals) reduced postoperative complications compared with sliding scale insulin (OR 3.39) in surgical patients with T2DM ^[243]^A1b (1b).

What NOT to Do

Do not use fenofibrate routinely in combination with statin; it does not reduce cardiovascular events (ACCORD: HR 0.92, 95% CI 0.79-1.08) and may cause harm in women ^[278]^A1b (1b).
Do not initiate saxagliptin in patients at risk for heart failure; it increased hospitalization for HF (HR 1.27, 95% CI 1.07-1.51) ^[251]^A1b (1b).
Do not target systolic BP <120 mm Hg with intensive therapy unless the patient can tolerate the increased risk of serious adverse events (3.3% vs 1.3%) ^[277]^A1b (1b).
Do not use colesevelam as first-line; it provides modest HbA1c reduction (-0.5%) with high pill burden and no cardiovascular outcome data ^[295]^A1a (1a).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line agent in patients with cardiorenal disease	ADA/EASD 2022 recommends SGLT2i or GLP-1 RA as first-line independent of metformin ^[77]^A1c	Prior ADA/EASD (2019) recommended metformin as first-line with SGLT2i/GLP-1 RA as second-line	Moderate (shift in paradigm)	Clinicians should evaluate for ASCVD, HF, or CKD at diagnosis and initiate cardiorenal-protective agents early
Intensive vs standard BP target	ACCORD supports <120 mm Hg for stroke reduction (HR 0.59) but increased adverse events ^[277]^A1b	ADVANCE supports standard target <140 mm Hg with perindopril/indapamide reduced mortality (HR 0.86, 95% CI 0.75-0.98) ^[280]^A1b	Mild (different populations)	Individualize BP target; closer to 130 mm Hg may be safe for most, with caution in older patients

Pearl: Initiate lifestyle modification and metformin at diagnosis, but promptly add SGLT2i or GLP-1 RA in patients with established ASCVD, CKD, or HF to reduce cardiovascular events and kidney failure; the legacy effect of early intensive glucose control persists for decades (UKPDS 80) ^[276]^A1b.

No major guideline disagreements identified for this topic in the reviewed evidence beyond the shift in first-line therapy for cardiorenal populations.

Key Drug Classes for Long-Term Management of T2DM

Drug class	Agent	Starting dose	Target/max dose	Renal adjustment	Key evidence (HR, 95% CI)	NNT (time)
SGLT2i	Canagliflozin	100 mg daily	100 mg daily	Avoid if eGFR <30	CREDENCE: primary outcome 0.70 (0.59-0.82) ^[275]^A1b	56 (2.62 yr)
SGLT2i	Dapagliflozin	10 mg daily	10 mg daily	Avoid if eGFR <25	CIMT reduction -0.058 mm ^[285]^A1b	Not calculable
SGLT2i	Empagliflozin	10 mg daily	25 mg daily	eGFR ≥20: continue	POST-CABG: AKI RR 0.57 (0.34-0.96) ^[100]^A1b	6 (per AKI event)
GLP-1 RA	Liraglutide	0.6 mg daily	1.8 mg daily	No adjustment	LEADER: CV death 0.78 (0.66-0.93) ^[107]^A1b	77 (3.8 yr)
GLP-1 RA	Semaglutide	0.25 mg weekly	1.0 mg weekly	No adjustment	NMA: HbA1c -1.39% vs placebo	Not calculable
Dual GIP/GLP-1 RA	Tirzepatide	2.5 mg weekly	15 mg weekly	No adjustment	NMA: HbA1c -1.96% vs placebo ^[48]^A1a	Not calculable
DPP-4i	Sitagliptin	100 mg daily	100 mg daily	eGFR <50: 50 mg	SAVOR-TIMI: MACE 1.00 (0.89-1.12) ^[251]^A1b	No benefit

History and Evolution of Treatment

▸UKPDS established metformin as first-line therapy and revealed the legacy effect: early intensive glucose control reduces long-term cardiovascular events even after glycemic differences are lost.
▸SGLT2 inhibitors and GLP-1 receptor agonists are the first drug classes to demonstrate cardiovascular and renal protection independent of glycemic control, leading to guideline recommendations as first-line in high-risk patients.

HY High Yield: The legacy effect from UKPDS proves that early intensive glycemic control confers vascular benefits that persist for at least a decade, even if control later wanes. This principle supports early intensification.

! Warning: SGLT2 inhibitors increase the risk of diabetic ketoacidosis (HR 1.78 in EMPRISE; NNH ~629 per year); this is a euglycemic ketoacidosis that can occur with modest glucose elevations. Educate patients to hold SGLT2i during intercurrent illness.

The treat-to-target framework described in the preceding section did not arise fully formed, it emerged from a half-century of therapeutic evolution punctuated by landmark failures and breakthroughs. Understanding this history grounds current practice in its evidentiary origin and explains why certain drug classes that were once mainstays are now relegated to second-line status.

The Era and the UKPDS Legacy

Before the 1990s, treatment of type 2 diabetes mellitus (T2DM) was largely algorithmic: start with a sulfonylurea, add insulin when β-cell function declined, and control blood pressure empirically. The United Kingdom Prospective Diabetes Study (UKPDS) changed everything. In newly diagnosed patients, intensive glucose control (sulfonylurea or insulin, targeting fasting plasma glucose <6 mmol/L) reduced microvascular risk by 25% compared with conventional diet therapy ^[276]^A1b. Cardiovascular benefit was not apparent during the trial but emerged during 10 years of post-trial follow-up: risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) appeared despite early loss of between-group glycemic differences, a phenomenon termed the legacy effect ^[276]^A1b. In overweight patients, metformin monotherapy produced even larger benefits: 33% reduction in myocardial infarction (P=0.005) and 27% reduction in all-cause mortality (P=0.002) ^[276]^A1b. Metformin was established as first-line pharmacotherapy, a position it retains today.

The Thiazolidinedione Promise and Peril

Thiazolidinediones (TZDs) arrived with great hope, targeting insulin resistance directly. Pioglitazone reduced the risk of major adverse cardiovascular events (MACE) in patients with established CVD (RR 0.80, 95% CI 0.7-0.9) and decreased albuminuria by 18.5% ^[299]^A1a. Yet enthusiasm was tempered by weight gain, fluid retention, and a 30% increase in hospitalization for heart failure (RR 1.30, 95% CI 1.1-1.6) ^[299]^A1a. Rosiglitazone was linked to excess cardiovascular events and largely withdrawn. Pioglitazone also raised fracture concern: although one randomized trial over 12 months found only a -1.2% difference in total hip BMD (P=0.03) and no change in bone turnover markers ^[36]^A1b, the CANVAS Program later reported a 26% increased fracture risk with (HR 1.26, 95% CI 1.04-1.52) that was not replicated in CREDENCE, suggesting the CANVAS finding may be chance ^[53]^B2b. TZDs fell from favor as safer, more cardioprotective options emerged.

Cardiovascular Safety Mandates and the DPP-4i Lesson

In 2008, the FDA mandated cardiovascular outcome trials (CVOTs) for all new glucose-lowering drugs. The first to report was SAVOR- 53 with saxagliptin, a DPP-4 inhibitor. It met noninferiority for MACE (HR 1.00, 95% CI 0.89-1.12) but unexpectedly increased hospitalization for heart failure (HR 1.27, 95% CI 1.07-1.51; NNH not calculable from reported data) ^[251]^A1b. This signaled that glycemic efficacy alone was insufficient, the class effect of DPP-4 inhibitors was neutral for MACE but possibly harmful for heart failure. Subsequent trials with alogliptin and sitagliptin confirmed neutrality. The DPP-4i class remains a well-tolerated, weight-neutral second-line option but lacks the organ-protective benefits of newer agents.

The SGLT2i and GLP-1 RA Revolution

The most transformative period in T2DM therapeutics began with EMPA-REG OUTCOME ( ) and LEADER ( ). In EMPA-REG OUTCOME, empagliflozin reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 14% (HR 0.86, 95% CI 0.74-0.99) and cardiovascular death by 38% (HR 0.62); NNT = 39 to prevent one cardiovascular death over 3.1 years. The benefit appeared within months, driven by hemodynamic and metabolic effects beyond glucose lowering. In LEADER, liraglutide reduced MACE by 13% (HR 0.87, 95% CI 0.78-0.97) and cardiovascular death by 22% (HR 0.78, 95% CI 0.66-0.93); NNT = 50 to prevent one cardiovascular death over 3.8 years ^[107]^A1b. Both classes also showed renal protection: CREDENCE (canagliflozin 100 mg daily) reduced the composite of end-stage kidney disease, doubling of creatinine, or renal/cardiovascular death by 30% (HR 0.70, 95% CI 0.59-0.82) over 2.62 years; NNT = 18 to prevent one primary outcome ^[275]^A1b. In the real-world EMPRISE study, empagliflozin vs DPP-4i was associated with lower risks of MI/stroke (HR 0.88), hospitalization for heart failure (HR 0.50), and MACE (HR 0.73), with larger absolute benefits in older patients and those with prior atherosclerotic cardiovascular disease or heart failure ^[258]^B3b. The mechanism of SGLT2i benefit may involve shifts in gut microbiota and plasma metabolites (e.g., increased short-chain fatty acid-producing bacteria, reduced glycochenodeoxycholate) ^[301]^A1b, and improved myocardial fibrosis by CMR-quantified extracellular volume (- with canagliflozin vs sitagliptin, P<0.001) ^[316]^A1b. GLP-1 receptor agonists now include once-weekly preparations such as dulaglutide, which in youth with T2DM reduced HbA1c by -0.9 percentage points at 26 weeks (vs +0.6 with placebo; P<0.001), with 51% achieving HbA1c <7.0% ^[41]^A1b. , a dual GIP/GLP-1 agonist, demonstrated reductions in NASH biomarkers (ALT, AST, keratin-18) and increased adiponectin ^[34]^A1b, and was associated with a 35% lower risk of compared with GLP-1 RAs alone (HR 0.65, 95% CI 0.44-0.96) ^[213]^B3b.

Evolving Prevention and Lifestyle Strategies

Landmark prevention trials established that T2DM can be delayed or prevented. The Finnish Diabetes Prevention Study showed that lifestyle intervention (weight loss, reduced fat, increased fiber and physical activity) reduced diabetes incidence by 58% (P<0.001) in adults with impaired glucose tolerance ^[309]^A1b. The STOP-NIDDM trial found that acarbose 100 mg three times daily reduced progression by 25% (HR 0.75, 95% CI 0.63-0.90) ^[313]^A1b. Voglibose 0.2 mg three times daily in Japanese patients reduced risk by 40% (HR 0.595) ^[117]^A1b. Curcumin, 9 months of intervention, prevented diabetes entirely in a prediabetic population (0% vs 16.4% in placebo; P<0.001) ^[271]^A1b. More recent dietary approaches include time-restricted eating (20-hour fast/4-hour eating window), which improved β-cell function by 14% (ISSI-2) and reduced HbA1c by -0.32% (P<0.001) over 6 weeks ^[171]^A1b. A carbohydrate-reduced high-protein diet augmented weight-loss-induced improvements in HbA1c (additional -0.18%), mean glucose, and liver fat ^[181]^A1b.

The Steno-2 study demonstrated that intensive multifactorial intervention, targeting glycemia, blood pressure, lipids, and microalbuminuria, slowed progression to nephropathy (odds ratio 0.27, 95% CI 0.10-0.75), retinopathy (OR 0.45, 95% CI 0.21-0.95), and (OR 0.32, 95% CI 0.12-0.78) ^[314]^A1b. The ACCORD Blood Pressure trial tested a systolic target <120 mm Hg vs <140 mm Hg; the primary outcome was not significantly reduced (HR 0.88, 95% CI 0.73-1.06), but stroke decreased by 41% (HR 0.59, 95% CI 0.39-0.89; P=0.01) at the cost of increased serious adverse events (3.3% vs 1.3%) ^[277]^A1b. ADVANCE showed that routine perindopril/indapamide reduced major vascular events by 9% (HR 0.91, 95% CI 0.83-1.00) and cardiovascular death by 18% (HR 0.82, 95% CI 0.68-0.98) ^[280]^A1b. The FIELD study found that fenofibrate 200 mg daily did not reduce coronary events significantly (HR 0.89, 95% CI 0.75-1.05) but did reduce total cardiovascular events by 11% (HR 0.89, 95% CI 0.80-0.99), mainly by fewer nonfatal MIs and revascularizations ^[312]^A1b, and lowered amputation risk by 36% (HR 0.64, 95% CI 0.44-0.94), especially minor amputations without large-vessel disease ^[118]^A1b. However, the ACCORD Lipid trial found no benefit of adding fenofibrate to (HR 0.92, 95% CI 0.79-1.08) ^[278]^A1b.

Abandoned Pathways and Lessons Learned

Several promising mechanisms failed to translate. TAK-875, a free fatty acid receptor 1 agonist, improved HbA1c with minimal hypoglycemia but was discontinued due to hepatotoxicity ^[49]^A1b. The 11β-HSD1 inhibitor AZD4017 reduced systemic 11β-HSD1 activity by 87% and showed signals of improved wound healing (48% smaller wound diameter at day 30) but remains investigational ^[304]^A1b. Intranasal insulin (40 IU) improved visuospatial memory and vasoreactivity in older adults with T2DM without affecting systemic glucose, but no long-term outcome data exist ^[244]^A1b. Oral magnesium supplementation (15 mmol/day for 6 weeks) did not improve insulin sensitivity in hypomagnesemic insulin-treated patients ^[317]^A1b. Bariatric surgery, while not a drug, remains the most effective intervention for T2DM remission, with mechanisms involving altered bile acid metabolism, incretin secretion, and gut microbiome shifts ^[324]^D5.

Pearl: The evolution of T2DM treatment is a shift from glucose-centric to complication-centric care; the greatest absolute risk reductions now come from SGLT2 inhibitors (NNT 18-39 for CV/renal outcomes) and GLP-1 receptor agonists (NNT 50 for CV death), not from traditional glucose-lowering agents.

Landmark Trials That Shaped T2DM Treatment

Trial	Intervention	Key Result	NNT/NNH	Year
UKPDS 34	Metformin in overweight new-onset T2DM	33% reduction in MI; 27% reduction in all-cause death	NNT ~14 for death over 10 yr	1998
ACCORD BP	Systolic BP target <120 vs <140 mm Hg	Stroke reduced 41% but more serious adverse events	NNT ~476 for stroke; NNH ~50 for serious AE	2010
ADVANCE	Perindopril/indapamide routine therapy	9% reduction in major vascular events; 18% reduction in CV death	NNT ~83 for vascular event over 4.3 yr	2007
SAVOR-TIMI 53	Saxagliptin vs placebo	No difference in MACE; increased HF hospitalization 27%	NNH ~143 for HF hospitalization	2013
EMPA-REG OUTCOME	Empagliflozin vs placebo	14% MACE reduction; 38% CV death reduction	NNT ~39 for CV death	2015
LEADER	Liraglutide vs placebo	13% MACE reduction; 22% CV death reduction	NNT ~50 for CV death	2016
CREDENCE	Canagliflozin 100 mg vs placebo	30% reduction in renal composite	NNT ~18 for renal/CV outcome over 2.6 yr	2019
SOLOIST-WHF	Sotagliflozin in recent HF decompensation	33% reduction in CV death + HF events	NNT ~10 for total events over 9 months	2020
Finnish DPS	Lifestyle (weight loss, diet, exercise)	58% reduction in diabetes incidence	NNT ~5 over 4 yr	2001
STENO-2	Multifactorial intensive therapy	Nephropathy: OR 0.27; retinopathy: OR 0.45	Not calculable from reported data	1999

Multiglandular Syndromes, Genetic Context and Co-Axis Effects

▸PCOS is a major independent risk factor for T2DM and CVD; universal OGTT screening is recommended by the Androgen Excess Society.
▸Mild autonomous cortisol secretion (MACS) defines a cortisol cutoff >50 nmol/L after dexamethasone suppression and requires T2DM screening in all affected patients.
▸Down syndrome quadruples T2DM incidence, with onset two decades earlier than the general population, driven by early obesity.

HY High Yield: In women with PCOS, a 75-g OGTT rather than HbA1c alone should be used for T2DM screening, as isolated fasting glucose misses a substantial proportion of impaired glucose tolerance [341].

The evolution of T2DM pharmacotherapy has redefined the disease as a condition of intersecting metabolic and hormonal axes. These interconnections, with the ovary, adrenal, thyroid, gut microbiome, and inflammatory cascades, require clinicians to think beyond glucose alone.

Polycystic Ovary Syndrome (PCOS)

PCOS is the most frequent endocrine disorder of reproductive-age women and a potent independent risk factor for T2DM. The Androgen Excess Society recommends universal screening with a 75-g oral glucose tolerance test (OGTT) rather than fasting glucose or HbA1c alone, because isolated fasting glucose misses a substantial proportion of impaired glucose tolerance ^[341]^A1c. In a prospective cohort, women with NIH-defined PCOS had a **BMI-adjusted HR for major adverse cardiovascular events of 2.47 ** by age 53 ^[7]^B2b. Genetic analyses reveal a positive overall genetic correlation between T2DM and PCOS (rg=0.31, p=1.63×10⁻⁸), partly independent of BMI, with 16 pleiotropic loci ^[353]^B2c. Women with PCOS exhibit lower circulating zinc-α2-glycoprotein (ZAG) and a paradoxical incretin profile (elevated total GIP, blunted late-phase GLP-1) that may mark early prediabetic states ^[338]^B2b^[197]^B3b. Even idiopathic hirsutism carries a marginal hazard for T2DM (HR 1.45) that attenuates with adjustment ^[342]^B2b. Routine screening of women with idiopathic hirsutism for metabolic outcomes is not recommended ^[342]^B2b.

Metabolic Syndrome and Familial Aggregation

Metabolic syndrome (MetS) confers an approximate 5-fold risk for incident T2DM ^[85]^D5. A sex- and race-specific MetS severity z-score predicts T2DM across the life course: each 1-unit increase in childhood MetS z-score raises the odds of adult T2DM by 2.7- to 2.8-fold (p<0.01) ^[344]^B2b. Changes in MetS severity during Diabetes Prevention Program interventions mediate the effect of lifestyle and on T2DM risk ^[218]^B2b. Notably, 15% of incident T2DM cases in the Whitehall II study had no components of MetS other than hyperglycemia, suggesting a second, unrelated pathophysiology ^[61]^C4. Familial T2DM risk (OR 2.13 per diabetic parent) is partially mediated by metabolic factors (11%) and a 62-allele genetic risk score (9%), but a large proportion remains unexplained ^[354]^B2b.

Adrenal Axis: Mild Autonomous Cortisol Secretion (MACS)

Adrenal incidentalomas are detected in 4-7% of abdominal CT scans. Current ESE guidelines define MACS as serum cortisol >50 nmol/L (>1.8 µg/dL) after 1-mg suppression, with all patients requiring screening for T2DM and ^[170]^A1c^[1]^A1c. MACS is associated with increased morbidity and mortality; surgical should be considered on an individualized basis when comorbidities are present ^[170]^A1c.

Thyroid and Other Endocrine Axes

Thyroid dysfunction, particularly subclinical hypothyroidism, accelerates T2DM progression through reduced basal metabolic rate and altered insulin sensitivity. The bidirectional relationship between HDL and T2DM involves hyperglycemia-induced deterioration of HDL functionality and, in turn, impaired HDL promoting pancreatic and skeletal muscle dysfunction ^[231]^D5. Chronic psychological stress, measured by the Perceived Stress Scale, is positively associated with HOMA-IR (β=0.463, 95%), though not with other MetS components ^[355]^B2a.

Genetic Syndromes

(DS) confers a 4-fold higher incidence of T2DM (incidence rate ratio 3.67, 95%), appearing at a median age of 38 years versus 53 years in controls, driven by earlier obesity (peak BMI 31.2 kg/m² in DS males at age 31) ^[178]^B2b. The apolipoprotein L (APOL) gene family, upregulated in islet inflammation via the JAK-STAT pathway, is overexpressed in beta cells from T2DM donors and may contribute to beta-cell damage ^[351]^D5.

Gut Microbiome, Incretin Axis, and Nutritional Factors

Obesity-related dysbiosis enhances energy harvest; lean-donor improves insulin sensitivity in metabolic syndrome, with a rise in butyrate-producing strains ^[348]^D5. improve glycemic control and lipid profiles in T2DM, though effects are strain-specific ^[350]^A1a. Mendelian randomization links genetic liability to T2DM with 12 diseases, including cholelithiasis (OR 1.09), acute pancreatitis (OR 1.08), and NAFLD (OR 1.29) ^[347]^B2b. Des-acyl ghrelin infusion suppresses acylated ghrelin and improves postprandial glycemia in obese T2DM, highlighting the ghrelin axis as a therapeutic target ^[339]^A1b. Vitamin D and calcium insufficiency may negatively influence glycemia; combined supplementation may offer modest benefit in high-risk populations with glucose intolerance, but evidence from trials is limited and heterogeneous ^[340]^B2a. Zinc supplementation shows no significant effect on insulin resistance or T2DM incidence in adults with insulin resistance (three RCTs, 128 participants) ^[94]^A1a.

Inflammation and Cellular Senescence

Chronic low-grade inflammation is central to T2DM pathogenesis; IL-1 antagonists improve β-cell function and may reduce cardiovascular events ^[87]^D5. The senolytic and senomorphic drug class, agents that selectively clear senescent cells, is under investigation in over 30 clinical trials for T2DM and its complications, potentially synergizing with existing therapies ^[264]^D5.

Hyperuricemia and Gout

In a meta-analysis of 87 studies (977,573 patients), the pooled prevalence of hyperuricemia in T2DM is 22.0% and of gout 6.0%, with highest rates in Africa and North America ^[132]^B2a. Risk factors include impaired renal function, obesity, dyslipidemia, hypertension, and alcohol; elevated HbA1c is inversely associated, likely due to uricosuric effects of glycosuria ^[132]^B2a. Routine serum uric acid monitoring is warranted.

Pearl: In women with PCOS, a 75-g OGTT is the preferred screening test for T2DM; HbA1c or fasting glucose alone will miss about one-third of glucose intolerance cases ^[341]^A1c.

Prevalence of Hyperuricemia and Gout in T2DM

Condition	Pooled Prevalence (95% CI)	Highest Region	Key Risk Factors
Hyperuricemia	22.0% (20.1-24.0%)	Africa, North America	Impaired renal function, obesity, dyslipidemia, hypertension, alcohol
Gout	6.0% (4.4-7.5%)	Not specified (male sex significant)	Male sex, MetS, obesity

Data from meta-analysis of 87 studies (N=977,573) ^[132]^B2a.

Complications and Long-term Sequelae

▸Cardiovascular disease is the leading cause of death; SGLT2i and GLP-1 RA reduce MACE and heart failure, with NNT ranging from 53 (liraglutide for CV death) to 187 per year (empagliflozin for HHF) depending on agent and baseline risk.
▸Microvascular complications (nephropathy, retinopathy) are reduced by intensive glycemic control (24% microvascular risk reduction with sulfonylurea-insulin in UKPDS) and by SGLT2i (canagliflozin reduced ESKD by 32%).
▸Infection burden is substantially higher (IRR 1.88 for T2DM hospitalization); vaccination, foot care, and prompt antibiotic therapy are critical preventive measures.

HY High Yield: The CREDENCE trial established canagliflozin as nephroprotective in albuminuric CKD (HR 0.70 for primary composite), an effect now extended to other SGLT2i. Screening for albuminuria and eGFR decline annually guides initiation.

! Warning: SGLT2i increase DKA risk by 78% (HR 1.78) in EMPRISE, even at modest glucose levels. Withhold during acute illness, surgery, or prolonged fasting. Educate patients on sick-day rules.

Having reviewed the genetic and syndromic contexts, the clinician must now confront the major source of morbidity in T2DM: its chronic complications. These span macrovascular (coronary artery disease, cerebrovascular disease, peripheral artery disease), microvascular (nephropathy, retinopathy, neuropathy), and systemic domains including infection, cognitive decline, and bone disease. Each requires targeted surveillance and intervention, guided by landmark trial evidence.

Macrovascular Complications

Cardiovascular disease remains the leading cause of death. Intensive glucose control in UKPDS reduced myocardial infarction by 15% and all-cause mortality by 13% over 10 years of follow-up ^[276]^A1b. A meta-analysis of five trials confirmed a 17% reduction in non-fatal myocardial infarction (OR 0.83, 0.75-0.93) with intensive glycemic control, but no significant effect on stroke or all-cause mortality ^[44]^A1a. Blood pressure lowering with a fixed perindopril-indapamide combination reduced major vascular events by 9% (HR 0.91, 0.83-1.00) and cardiovascular death by 18% (HR 0.82, 0.68-0.98) in ADVANCE; over 4.3 years the absolute risk reduction for the primary composite was 1.3%, NNT = 77 ^[280]^A1b. Targeting systolic BP <120 mm Hg in ACCORD did not reduce the primary composite (HR 0.88, 0.73-1.06) but lowered stroke by 41% (HR 0.59, 0.39-0.89), albeit with more serious adverse events (3.3% vs 1.3%; NNH = 50) ^[277]^A1b.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) now provide organ protection beyond glucose lowering. In the EMPRISE study, versus DPP-4 inhibitors reduced hospitalization for heart failure (HHF) by 50% (HR 0.50, 0.44-0.56; RD -5.35 per 1000 person-years; NNT ≈ 187 per year) and MACE by 27% (HR 0.73, 0.62-0.86) ^[258]^B3b. in LEADER reduced the composite of cardiovascular death, nonfatal MI, or stroke by 13% (HR 0.87, 0.78-0.97; absolute rates 13.0% vs 14.9% over 3.8 years; NNT = 53) and cardiovascular death by 22% (HR 0.78, 0.66-0.93; NNT = 77) ^[107]^A1b. Sotagliflozin, a dual SGLT1/2 inhibitor, lowered total cardiovascular deaths and HHF events in patients with recent worsening heart failure (SOLOIST-WHF: HR 0.67, 0.52-0.85) and in those with chronic kidney disease (SCORED: HR 0.74, 0.63-0.88) ^[249]^A1b^[250]^A1b. In contrast, saxagliptin increased HHF by 27% (HR 1.27, 1.07-1.51; absolute 3.5% vs 2.8% over 2.1 years; NNH = 143) ^[251]^A1b. Visit-to-visit lipid variability independently predicts heart failure risk; participants in the highest quartile of LDL cholesterol variability had a 76% higher risk (aHR 1.76, 1.27-2.42) ^[364]^B2b.

Peripheral artery disease (PAD) and amputation risk are elevated. GLP-1 RA use in patients with PAD was associated with a 27% lower risk of major limb events (RR 0.73, 0.65-0.82) and 24% lower risk of (RR 0.76, 0.66-0.87) ^[80]^B2a. Fenofibrate reduced first amputation by 36% (HR 0.64, 0.44-0.94), driven by minor amputations without large-vessel disease (HR 0.53, 0.30-0.94) ^[118]^A1b.

Microvascular Complications

Nephropathy progresses to end-stage kidney disease (ESKD) in a substantial fraction. The CREDENCE trial demonstrated that 100 mg daily reduced the primary composite of ESKD, doubling of creatinine, or renal/cardiovascular death by 30% (HR 0.70, 0.59-0.82; absolute rates 43.2 vs 61.2 per 1000 patient-years; NNT ≈ 21 over 2.62 years) and the renal-specific composite by 34% (HR 0.66, 0.53-0.81) ^[275]^A1b. ESKD risk alone fell by 32% (HR 0.68, 0.54-0.86). Younger age at diabetes diagnosis confers higher lifetime risk of microvascular disease; each 1-year increase in age at diagnosis reduces microvascular risk by 5% (OR 0.95 per year) ^[183]^B2a. Phenotypic age acceleration, measured by routine biomarkers, is associated with a 30% higher risk of incident (RR 1.30, 1.10-1.54) and a 56% higher risk of incident retinopathy (RR 1.56, 1.10-2.23) ^[143]^B2b. Women with prior gestational diabetes have a more than twofold increased risk of vision-threatening after developing T2DM (aHR 2.28, 1.06-4.92) ^[145]^B2b.

Intensive glycemic control produces the largest microvascular benefit. In UKPDS, sulfonylurea-insulin therapy reduced microvascular complications by 24% at 10 years (P=0.001), and reduced any diabetes-related end point by 21% (P=0.01) ^[276]^A1b. A meta-analysis confirmed a 15% reduction in coronary heart disease (OR 0.85, 0.77-0.93) with intensive control but no significant stroke reduction ^[44]^A1a.

Infection and Cognitive Dysfunction

Infection risk is substantially elevated. Compared with the general population, patients with T2DM have an 88% higher rate of infection-related hospitalization (IRR 1.88, 1.83-1.92) and those with T1DM a 271% higher rate (IRR 3.71) ^[114]^B2b. An estimated 12% of infection-related deaths are attributable to diabetes. Vaccination (influenza, pneumococcal, hepatitis B) and prompt antibiotic therapy are essential.

Cognitive impairment is increasingly recognized. A risk score incorporating microvascular disease, diabetic foot, cerebrovascular disease, cardiovascular disease, acute metabolic events, depression, age, and education predicts 10-year dementia risk ranging from 5.3% (lowest score) to 73.3% (highest score) ^[121]^B2b. Tight glycemic control and of vascular risk factors may attenuate decline, though trial data are limited.

Complications Overview

Complication	Frequency	Prevention	Management
Major adverse cardiovascular events	10-year MACCE ~11-15% in T2DM ^[141]^B2b^[270]^A1b	Intensive glycemic control ^[276]^A1b, BP control ^[280]^A1b, SGLT2i ^[258]^B3b, GLP-1 RA ^[107]^A1b, statin/fenofibrate ^[118]^A1b	Standard CVD therapies, revascularization, antiplatelet agents
Heart failure	5-year risk ~10-15%	SGLT2i (empagliflozin RD -5.35/1000 pt-yrs ^[258]^B3b), sotagliflozin ^[249]^A1b	Diuretics, RAAS blockade, SGLT2i, guideline-directed medical therapy
Stroke	~0.5% annual in ACCORD ^[277]^A1b	Intensive BP to <120 mm Hg (HR 0.59) ^[277]^A1b, SGLT2i in AF (HR 0.83) ^[360]^B2b	Antiplatelet, thrombolysis, risk factor control
Nephropathy/CKD	ESKD event rate 61.2/1000 pt-yrs (placebo CREDENCE) ^[275]^A1b	SGLT2i (canagliflozin HR 0.70) ^[275]^A1b, RAAS blockade, glycemic control	SGLT2i, RAAS blockade, prepare for renal replacement
Retinopathy	Incident DR ~30% higher with PhenoAge acceleration ^[143]^B2b	Intensive glycemic control ^[276]^A1b, lipid control	Laser photocoagulation, anti-VEGF, glycemic optimization
Lower extremity amputation	~1-2% over 5 years in FIELD ^[118]^A1b	Fenofibrate (HR 0.64) ^[118]^A1b, GLP-1 RA (RR 0.76) ^[80]^B2a	Revascularization, wound care, smoking cessation
Serious infection	Hospitalization IRR 1.88 vs non-diabetes ^[114]^B2b	Vaccination, foot care, early antibiotic therapy	Source control,

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Intensive BP target (<120 mm Hg)	ACCORD: primary composite not significant, stroke benefit ^[277]^A1b	ESC/EASD guidelines recommend target <130/80 mm Hg	Neutral	Shared decision-making; higher adverse event rate (3.3% vs 1.3%) limits routine use
GLP-1 RA post-MI effect	Meta-analysis showed all-cause mortality HR 0.67 (0.49-0.90) ^[368]^A1a	Significance lost with Hartung-Knapp-Sidik-Jonkman adjustment (P=0.05)	Weak	Benefit signals require confirmation; use based on overall CV risk
SGLT2i and DKA risk	EMPRISE: DKA HR 1.78 (1.44-2.19) ^[258]^B3b	Absolute risk low (~1.6 per 1000 pt-yrs)	Consistent across trials	Educate patients; withhold during acute illness

Pearl: The CREDENCE trial demonstrated that canagliflozin 100 mg daily reduced the risk of kidney failure by 32% (HR 0.68, 0.54-0.86) over 2.62 years in patients with albuminuric CKD, establishing SGLT2i as a cornerstone of nephroprotection.

Prognosis, Natural History and Prevention

▸Younger age at diagnosis (especially <40 years) is associated with higher risk of mortality and vascular complications, with each 1-year increase in age at diagnosis reducing risk by 3-5%.
▸Lifestyle modification reduces diabetes incidence by 43% (RR 0.57), but pharmacologic options (pioglitazone, metformin/rosiglitazone, voglibose, vitamin D) provide additional benefit, with NNT as low as 4 for combination therapy.
▸Bariatric surgery produces the highest rates of diabetes remission and prevention, even in patients with BMI <35 kg/m².

HY High Yield: In patients with impaired glucose tolerance, the combination of rosiglitazone 2 mg plus metformin 500 mg twice daily yielded an **NNT of 4** over 3.9 years to prevent one case of diabetes, while also improving insulin sensitivity and promoting regression to normoglycemia [119].

! Warning: Pioglitazone for diabetes prevention is not FDA-approved for this indication and carries risks of weight gain (mean 3.9 kg), edema (12.9%), and potential fracture risk; use only after shared decision-making in patients with IGT and high cardiovascular risk [111][299].

The natural history of type 2 diabetes imposes a heavy burden, but the disease trajectory can be substantially altered by early detection and aggressive prevention. The long-term prognosis is dominated by the risk of microvascular and macrovascular complications, which are amplified by younger age at diagnosis and longer disease duration. Each 1 year increase in age at diagnosis reduces the risk of all-cause mortality by 4%, macrovascular disease by 3%, and microvascular disease by 5%, after adjustment for current age ^[183]^B2a. Youth-onset type 2 diabetes carries a particularly aggressive course: incidence rates among US adolescents rose 7.1% annually from 2002 to 2012, and these young patients face rapid progression of nephropathy, retinopathy, and cardiovascular disease ^[377]^B2c^[257]^D5. Higher fasting C-peptide levels at diagnosis are associated with a lower risk of incident microvascular complications (retinopathy HR 0.33, nephropathy HR 0.27, neuropathy HR 0.39) but no survival benefit ^[373]^B2b.

Primary Prevention

Lifestyle modification remains the cornerstone. In a Cochrane meta-analysis of 12 trials, diet plus physical activity reduced the incidence of type 2 diabetes by 43% (RR 0.57, 95% CI 0.50 to 0.64) over 2-6 years ^[27]^A1a. However, the effect of primary care-based lifestyle programs on diabetes incidence is less certain (RR 0.82, 95% CI 0.65-1.02) ^[176]^A1a. Digital coaching yields similar weight loss to in-person diabetes prevention programs (1-year weight loss to) ^[103]^B2a.

Several pharmacologic agents prevent progression from to diabetes. Pioglitazone reduced the annual conversion rate from 7.6% to 2.1% (HR 0.28, 95% CI 0.16-0.49; NNT = 18 over 2.4 years) in the ACT NOW trial ^[111]^A1b. Low-dose combination rosiglitazone 2 mg plus 500 mg twice daily halved the risk (RR 0.34, 95%; NNT = 4 over 3.9 years) ^[119]^A1b. Voglibose 0.2 mg three times daily reduced progression in Japanese individuals (HR 0.60) ^[117]^A1b. Curcumin (1.5 g/day) prevented all cases of diabetes over 9 months in a small Thai trial (0% vs 16.4% in placebo) ^[271]^A1b. Vitamin D supplementation reduces the risk modestly (RR 0.89), with benefit confined to nonobese individuals (RR 0.73, 95% CI 0.57-0.92) ^[370]^A1a. Testosterone therapy in men with impaired glucose tolerance and low testosterone reduced diabetes risk at 2 years (OR 0.53, 95% CI 0.35-0.79), with 65% of the effect mediated by fat mass reduction ^[172]^A1b.

Bariatric surgery produces the most dramatic prevention. In patients with BMI <35 kg/m², meta-analyses of randomized trials show superior type 2 diabetes remission and glycemic control compared with medical therapy, with comparable safety ^[105]^D5. Single Anastomosis Sleeve Ileal bypass yields high diabetes remission rates (OR 4.20, 95% CI 2.17-8.11) ^[379]^B2a.

Screening and Risk Stratification

Screening for prediabetes should include measurement of fasting glucose, HbA1c, or 2-hour glucose after a 75 g oral glucose tolerance test. The HbA1c thresholds remain debated: a systematic review supports a graded risk continuum, with 5.7-6.4% identifying a broader population for low-intensity advice and 6.0-6.4% stratifying those at highest near-term risk ^[380]^B2a. The Endocrine Society recommends screening patients with metabolic risk factors (waist circumference, blood pressure, lipids, fasting glucose) every 1-2 years ^[369]^A1c. Family cascade screening is especially important in high-risk ethnic groups and in women with a history of gestational diabetes or , who carry a 2.2-fold increased risk of subsequent type 2 diabetes ^[310]^A1a. AI-based prediction models incorporating fasting glucose and BMI show pooled accuracy of 0.85 (95% CI 0.79-0.90) for predicting progression from gestational diabetes to type 2 diabetes ^[204]^B2a.

Pearl: Younger age at diagnosis (<40 years) confers a 3-4% higher relative risk of mortality and vascular complications per year of earlier onset; early and sustained prevention, through lifestyle, pharmacotherapy, or metabolic surgery, should be prioritized in this group.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Lower HbA1c threshold for prediabetes	ADA: 5.7% (39 mmol/mol) ^[380]^B2a	Some guidelines: 6.0% (42 mmol/mol) ^[380]^B2a	Conflicting evidence from cohort studies	5.7% identifies more individuals but includes many at low short-term risk; 6.0% better targets high-risk individuals for intensive prevention ^[380]^B2a
Role of pioglitazone in primary prevention	Endocrine Society: consider in high-risk patients ^[299]^A1a	Safety concerns: weight gain, edema, fracture risk; not approved by FDA for this indication ^[111]^A1b	Moderate evidence from ACT NOW	May be used off-label in selected patients with IGT and high CVD risk, weighing risks of weight gain and fluid retention ^[111]^A1b^[299]^A1a

Selected Prevention Strategies for Type 2 Diabetes in Prediabetes

Intervention	Population	Effect Size	NNT (time frame)	Key Safety Concerns	Source
Lifestyle (diet + physical activity)	IGT or IFG	RR 0.57 (0.50-0.64)	~6 (3 years)	None	^[27]^A1a
Pioglitazone 45 mg/day	IGT	HR 0.28 (0.16-0.49)	18 (2.4 years)	Weight gain +3.9 kg, edema 12.9%	^[111]^A1b
Rosiglitazone 2 mg + metformin 500 mg twice daily	IGT	RR 0.34 (0.20-0.59)	4 (3.9 years)	Diarrhea 16% vs 6% placebo	^[119]^A1b
Voglibose 0.2 mg three times daily	IGT (Japanese)	HR 0.60 (0.43-0.82)	20 (1 year)	GI adverse events common	^[117]^A1b
Vitamin D supplementation	Prediabetes (nonobese)	RR 0.73 (0.57-0.92)	15 (3 years)	None significant	^[370]^A1a
Bariatric/metabolic surgery	BMI <35 kg/m² with T2DM	Diabetes remission OR 4.20 (2.17-8.11)	2-3 (1-2 years)	Operative complications; higher complication rate for SASI bypass	^[105]^D5^[379]^B2a

Special Populations, Pregnancy and Fertility

▸Women with gestational diabetes have a 7-fold higher risk of progressing to type 2 diabetes; postpartum glucose testing and lifestyle intervention are critical, with lactation exerting a protective effect.
▸In pregnant women with pre-existing type 2 diabetes, insulin remains first-line; continuing metformin does not increase composite neonatal adverse outcomes, though a possible signal for small-for-gestational-age infants warrants attention.
▸GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are effective in pediatric obesity and youth-onset T2DM without adverse effects on linear growth or pubertal progression.
▸In elderly patients with T2DM, waist circumference is a better risk indicator than BMI; the decline in hypoglycemia hospitalizations after 2009 likely reflects reduced sulfonylurea use.

HY High Yield: Women with gestational diabetes have a 7-fold increased risk of future type 2 diabetes (RR 7.43); postpartum glucose testing at 6-12 weeks is mandatory, and lactation reduces this risk.

! Warning: In elderly patients, sulfonylurea use has been linked to a rise in hypoglycemia hospitalizations that only began to decline after 2009; deprescribe sulfonylureas when safer alternatives (GLP-1 RAs, SGLT2is) are available.

The natural history and of type 2 diabetes are fundamentally reshaped by physiologic states, pregnancy, growth, aging, and the surgical stress response, each demanding tailored glycemic targets, medication adjustments, and vigilant monitoring.

Pregnancy: Pre-existing Diabetes and Gestational Diabetes

Women with pre-existing type 2 diabetes (T2DM) face elevated risks of congenital malformations and adverse pregnancy outcomes; strict preconception glycemic control reduces these risks ^[32]^A1c^[399]^A1a. The Endocrine Society suggests asking about pregnancy intention at every reproductive-age visit (GRADE 2 | ⊕OOO) ^[32]^A1c. Insulin remains first-line therapy in pregnancy because oral agents lack long-term safety data, though continuing is reasonable. The MiTy trial emulation found no increased risk of a neonatal composite outcome (preterm birth, respiratory distress, hypoglycemia, NICU admission) with metformin continuation (adjusted RR 0.92, 95% CI 0.81-1.03); a possible signal for small-for-gestational-age infants warrants caution ^[323]^B2b. Adding metformin to insulin lowered large-for-gestational-age risk (2 RCTs, 1126 patients) ^[383]^A1a. Hybrid closed-loop insulin pumps improve overnight time in range and time below range compared with standard care ^[383]^A1a. Delivery before 39 weeks (especially <38 weeks) increases neonatal complications ^[383]^A1a.

Gestational diabetes mellitus (GDM) affects up to 25% of pregnancies and is a powerful harbinger of future T2DM. Women with GDM have a 7-fold higher risk of progressing to T2DM (RR 7.43) ^[8]^A1a; pooled incidence is 9.0% (95% CI 4%-13%), with an adjusted estimate of 6.9% after addressing publication bias ^[398]^B2a. Risk is amplified by obesity (BMI >25: effect size 2.58), insulin use during pregnancy (2.21), family history (2.00), and abnormal OGTT values (4.28) ^[398]^B2a. An abnormal fasting glucose on OGTT confers the highest future T2DM risk (aHR 14.09 vs. 9.22 for abnormal 2-h value) ^[15]^B2b. Postpartum glucose testing is essential, yet uptake is poor; reminder systems increase OGTT completion from 14% to 57% (RR 4.23 for woman+physician reminder) ^[212]^A1a. Lactation is protective against progression ^[331]^B2a. Lifestyle interventions are cost-saving (AU$1.22 return per dollar) ^[397]^D5; myo-inositol supplementation may reduce GDM incidence (RR 0.53, low certainty) ^[140]^A1a.

Pediatrics: Youth-Onset Type 2 Diabetes

Youth-onset T2DM is increasing, with more girls than boys diagnosed during adolescence ^[394]^C4. Current ADA screening criteria have low sensitivity (41.7%) for detecting impaired glucose tolerance; many youth with dysglycemia have normal fasting glucose, making OGTT or HbA1c essential ^[390]^C4. Pubertal insulin resistance contributes, but spontaneous normalization can occur, complicating definitions ^[404]^D5. Lifestyle modification is first-line. Pharmacologic options include metformin and GLP-1 receptor agonists: 1.8 mg/day and dulaglutide improve HbA1c in youth with T2DM ^[82]^A1a. 2.4 mg/week and liraglutide 3.0 mg/day also reduce BMI in adolescents with obesity ^[82]^A1a. No significant adverse effects on linear growth or pubertal progression were reported ^[82]^A1a.

Elderly: Phenotype and Individualized Targets

In elderly patients with T2DM, the BMI paradox confounds risk assessment: BMI ≥30 kg/m² was associated with lower composite outcome (stroke, MI, death) risk (HR 0.824), but waist circumference ≥100 cm (men) / ≥95 cm (women) predicted higher risk (HR 1.434) ^[361]^B2b. Hypoglycemia hospitalizations in older adults rose 8.59% annually from 1998-2009, then declined 8.05% yearly through 2013, likely due to reduced sulfonylurea use ^[384]^B3b. GLP-1 RAs reduce cardiovascular events in older patients and are safe ^[38]^A1a. Weight loss through lifestyle (adequate protein, resistance exercise) improves frailty without harm ^[346]^D5. Vitamin D sufficiency is associated with lower prevalence of metabolic syndrome (OR 0.61 for 25OHD ≥75 nmol/L vs. <50 nmol/L) ^[393]^C4.

Fertility, , and Cardiometabolic Risk

Polycystic ovary syndrome (PCOS) independently increases odds of GDM (OR 2.1) and T2DM (OR 8.8) ^[387]^C4. A history of infertility, especially due to ovulation disorders (HR 1.43) or tubal factor (HR 1.34), is associated with higher incident T2DM ^[320]^B2b. Early menopause (<45 years) amplifies CVD risk in women with T2DM, particularly in Black women (HR for ASCVD 1.29 vs. 1.10 without T2DM) ^[389]^B2b.

Perioperative Stress and Glycemic Management

Elevated HbA1c is associated with perioperative complications: HbA1c ≥8.5% independently predicted unplanned readmission after elective anterior cervical and fusion (OR 1.72); HbA1c 7.5-8.49% was linked to sepsis (OR 2.53) ^[403]^B2b. Preoperative optimization to HbA1c <8% is prudent, though no single cutoff robustly discriminates risk.

Controversies and Guideline Disagreement: GDM Diagnostic Criteria

Question	Position A (IADPSG)	Position B (Diabetes Canada)	Strength	Implication
Which OGTT criteria predict T2DM risk best?	One-step 75-g OGTT; lower threshold captures more GDM cases	Two-step approach with stricter fasting cutoff	Women meeting Diabetes Canada criteria have higher future T2DM incidence (18.74 vs. 14.07 per 1000 person-years) ^[15]^B2b	Choice affects GDM prevalence and postpartum risk stratification

Pearl: For any woman with GDM, the single strongest predictor of progression to T2DM is the presence of an abnormal fasting glucose on the diagnostic OGTT; a normal 2-hour value does not rule out future risk, and postpartum testing with fasting glucose or HbA1c at 6-12 weeks should never be deferred.

Risk Factors for Progression from Gestational Diabetes to Type 2 Diabetes

Risk Factor	Effect Size (95% CI)	Source
Abnormal gestational OGTT results	ES 4.28 (NR)	^[398]^B2a
Maternal BMI > 25 kg/m²	ES 2.58 (NR)	^[398]^B2a
Insulin requirement during pregnancy	ES 2.21 (NR)	^[398]^B2a
Positive family history of diabetes	ES 2.00 (NR)	^[398]^B2a
Fasting glucose abnormality (vs 2-h)	aHR 14.09 (12.46-15.93)	^[15]^B2b
Lactation (protective)	Reduced risk (qualitative)	^[331]^B2a

References

[1]
Fassnacht M, Arlt W, Bancos I et al.. “Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.” European journal of endocrinology (2016). PMID: 27390021 ↗
L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[2]
Balasubramanian P, Wanner C, Ferreira JP et al.. “Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?” The Journal of clinical endocrinology and metabolism (2022). PMID: 35290464 ↗
L1RCTCited in: Definition, Classification and Axis Nomenclature, History and Evolution of Treatment
[3]
Raz I, Ceriello A, Wilson PW et al.. “Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia.” Diabetes care (2011). PMID: 21593301 ↗
L2RCTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[4]
Tanabe H, Hirai H, Saito H et al.. “Detecting Sarcopenia Risk by Diabetes Clustering: A Japanese Prospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35908291 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[5]
Ebeling PR, Adler RA, Jones G et al.. “MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D.” European journal of endocrinology (2018). PMID: 30131372 ↗
L5SR_OBSCited in: Definition, Classification and Axis Nomenclature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[6]
Beulens JW, Patel A, Vingerling JR et al.. “Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.” Diabetologia (2009). PMID: 19633827 ↗
L1RCTCited in: Definition, Classification and Axis Nomenclature
[7]
Ollila MM, Arffman RK, Korhonen E et al.. “Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study.” European journal of endocrinology (2023). PMID: 37436934 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[8]
Bellamy L, Casas JP, Hingorani AD et al.. “Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis.” Lancet (London, England) (2009). PMID: 19465232 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Special Populations, Pregnancy and Fertility
[9]
Hoek AG, Dal Canto E, Wenker E et al.. “Epidemiology of heart failure in diabetes: a disease in disguise.” Diabetologia (2024). PMID: 38334818 ↗
L5SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[10]
Nouwen A, Winkley K, Twisk J et al.. “Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis.” Diabetologia (2010). PMID: 20711716 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors
[11]
Gurgoglione FL, Pitocco D, Montone RA et al.. “Microvascular Complications Are Associated With Coronary Collateralization in Type 2 Diabetes and Chronic Occlusion.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37417706 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[12]
Golden SH, Brown A, Cauley JA et al.. “Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22730516 ↗
L5OTHERCited in: Definition, Classification and Axis Nomenclature
[13]
Zeitler P. “Update on nonautoimmune diabetes in children.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19584196 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature
[14]
Yin T, Kuo SC, Chang YY et al.. “Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28368479 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature
[15]
Hiersch L, Shah BR, Berger H et al.. “Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus.” Diabetes care (2021). PMID: 34131049 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Special Populations, Pregnancy and Fertility
[16]
Bianchi C, Miccoli R, Bonadonna RC et al.. “Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance.” Diabetes care (2012). PMID: 22912427 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature
[17]
Zhang J, Lin Z, Zhong S et al.. “Traditional Chinese medicine syndrome patterns and associated factors in adults with type 2 diabetes and metabolic syndrome: a data-driven analysis.” Frontiers in endocrinology (2026). PMID: 42388871 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[18]
Leslie RD, Palmer J, Schloot NC et al.. “Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.” Diabetologia (2016). PMID: 26498592 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[19]
Mori T, Zaharia OP, Straßburger K et al.. “Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypes.” Diabetologia (2025). PMID: 40715719 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[20]
Kostev K, Rathmann W. “Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis.” Diabetologia (2012). PMID: 23052061 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature
[21]
de Victoria Carazo JM, Guirao Arrabal E, Montero-Alonso MÁ et al.. “Incidence, mortality and risk factors in COVID-19-associated pulmonary aspergillosis (CAPA): an umbrella review and meta-meta-analyses (2020-2025).” Respiratory medicine (2026). PMID: 42302999 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Acute Management and Endocrine Emergencies
[22]
Rodriguez-Hilarion JA, Ramos-Castaneda JA, Duran Aguero S et al.. “Effect of Ultra-Processed Foods Consumption on Human Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses.” Nutrition reviews (2026). PMID: 42247240 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
[23]
Chen A, Zhao K, Ceban F et al.. “Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2026). PMID: 42087044 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
[24]
White RT, Henriquez P, Innocent B et al.. “Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.” Pharmacotherapy (2026). PMID: 41947645 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
[25]
Wang X, You S, Tang S et al.. “Depression comorbidity in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41918972 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature
[26]
Richter B, Hemmingsen B, Metzendorf MI et al.. “Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.” The Cochrane database of systematic reviews (2018). PMID: 30371961 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History and Prevention
[27]
Hemmingsen B, Gimenez-Perez G, Mauricio D et al.. “Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2017). PMID: 29205264 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[28]
Chew BH, Vos RC, Metzendorf MI et al.. “Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2017). PMID: 28954185 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification
[29]
Hemmingsen B, Schroll JB, Lund SS et al.. “Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23633364 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
[30]
Rolim LC, da Silva EM, Flumignan RL et al.. “Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.” The Cochrane database of systematic reviews (2019). PMID: 31201734 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, History and Evolution of Treatment
[31]
Hemmingsen B, Lund SS, Gluud C et al.. “Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2011). PMID: 21678374 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature
[32]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652453 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[33]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” European journal of endocrinology (2025). PMID: 40652450 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[34]
Hartman ML, Sanyal AJ, Loomba R et al.. “Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.” Diabetes care (2020). PMID: 32291277 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[35]
Burggraaf B, Pouw NMC, Fernández Arroyo S et al.. “Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.” European journal of endocrinology (2022). PMID: 35312632 ↗
L2RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[36]
Grey A, Bolland M, Fenwick S et al.. “The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial.” European journal of endocrinology (2013). PMID: 24217934 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
[37]
Piccoli GF, Mesquita LA, Stein C et al.. “Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33248445 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[38]
Pinto LC, Rados DV, Remonti LR et al.. “Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32797182 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Special Populations, Pregnancy and Fertility
[39]
Mantovani A, Morandin R, Lando MG et al.. “Sodium-Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies.” Diabetes care (2025). PMID: 40392994 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
[40]
Francque SM, Bedossa P, Ratziu V et al.. “A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.” The New England journal of medicine (2021). PMID: 34670042 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[41]
Arslanian SA, Hannon T, Zeitler P et al.. “Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.” The New England journal of medicine (2022). PMID: 35658022 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[42]
Larsen CM, Faulenbach M, Vaag A et al.. “Interleukin-1-receptor antagonist in type 2 diabetes mellitus.” The New England journal of medicine (2007). PMID: 17429083 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[43]
Solomon SD, Uno H, Lewis EF et al.. “Erythropoietic response and outcomes in kidney disease and type 2 diabetes.” The New England journal of medicine (2010). PMID: 20843249 ↗
L2RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[44]
Ray KK, Seshasai SR, Wijesuriya S et al.. “Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.” Lancet (London, England) (2009). PMID: 19465231 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[45]
Morales DR, Bu F, Viernes B et al.. “Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.” Diabetes care (2025). PMID: 40465422 ↗
L3COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[46]
Anthony MS, Aroda VR, Parlett LE et al.. “Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.” Diabetes care (2024). PMID: 38363873 ↗
L3COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[47]
Bakker LE, Sleddering MA, Schoones JW et al.. “Pathogenesis of type 2 diabetes in South Asians.” European journal of endocrinology (2013). PMID: 23939919 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[48]
Karagiannis T, Malandris K, Avgerinos I et al.. “Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.” Diabetologia (2024). PMID: 38613667 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[49]
Burant CF, Viswanathan P, Marcinak J et al.. “TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2012). PMID: 22374408 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[50]
Keech AC, Mitchell P, Summanen PA et al.. “Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17988728 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
[51]
Pratley RE, Nauck M, Bailey T et al.. “Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.” Lancet (London, England) (2010). PMID: 20417856 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[52]
Zhu D, Ma J, Wang W et al.. “Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.” Diabetologia (2025). PMID: 41272211 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, History and Evolution of Treatment
[53]
Zhou Z, Jardine M, Perkovic V et al.. “Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.” Diabetologia (2019). PMID: 31399845 ↗
L2RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
[54]
Kuss O, Opitz ME, Brandstetter LV et al.. “How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.” Diabetologia (2023). PMID: 37338539 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
[55]
Kramer CK, Zinman B, Retnakaran R. “Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis.” The lancet. Diabetes & endocrinology (2013). PMID: 24622264 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
[56]
Houghton D, Hardy T, Stewart C et al.. “Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes.” Diabetologia (2018). PMID: 29754286 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[57]
Salama M, Balagopal B, Fennoy I et al.. “Childhood Obesity, Diabetes. and Cardiovascular Disease Risk.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37319430 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[58]
Pohlman N, Patel PN, Essien UR et al.. “Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40388382 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[59]
Kasher Meron M, Hornik-Lurie T, Twig G et al.. “GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41665888 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[60]
Chia CW, Egan JM. “Incretin-based therapies in type 2 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18628530 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[61]
Rottenkolber M, Gar C, Then C et al.. “A Pathophysiology of Type 2 Diabetes Unrelated to Metabolic Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33515032 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[62]
Tong J, Li N, Hu F et al.. “Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study.” Diabetes care (2026). PMID: 41259721 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae
[63]
Gonzalez JS, Bebu I, Krause-Steinrauf H et al.. “Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).” Diabetes care (2024). PMID: 38416773 ↗
L1OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[64]
Bolli GB, Home PD, Porcellati F et al.. “The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.” Diabetes care (2025). PMID: 40116796 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[65]
Chakkera HA, Weil EJ, Pham PT et al.. “Can new-onset diabetes after kidney transplant be prevented?” Diabetes care (2013). PMID: 23613600 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[66]
Tian L, Li X, Zeng X et al.. “Increased Thyroid Hormone Action Alleviates Hippocampal Damage by Downregulating Neuronal Type I Interferon Signaling/Necroptosis in Diabetes-Associated Cognitive Dysfunction.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 39104259 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[67]
Alonso-Ventura V, Civeira F, Alvarado-Rosas A et al.. “A Cross-Sectional Study Examining the Parametric Thyroid Feedback Quantile Index and Its Relationship with Metabolic and Cardiovascular Diseases.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 35891590 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
[68]
González-Luis A, Llinares-Arvelo V, Martínez-Alberto CE et al.. “Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment.” European journal of endocrinology (2025). PMID: 41166543 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[69]
Allin KH, Nielsen T, Pedersen O. “Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus.” European journal of endocrinology (2014). PMID: 25416725 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[70]
Kurstjens S, de Baaij JH, Bouras H et al.. “Determinants of hypomagnesemia in patients with type 2 diabetes mellitus.” European journal of endocrinology (2016). PMID: 27707767 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[71]
Van Gaal LF, Gutkin SW, Nauck MA. “Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?” European journal of endocrinology (2008). PMID: 18322302 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[72]
Emara A, Emara M, Mansour A et al.. “Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.” Diabetology & metabolic syndrome (2026). PMID: 42363271 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[73]
Rosen CJ, Ingelfinger JR. “GLP-1 Receptor Agonists.” The New England journal of medicine (2026). PMID: 41931049 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[74]
Jun JE, Oh DH, Jeong IK et al.. “Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.” Frontiers in endocrinology (2026). PMID: 42388875 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment
[75]
Wu X, Yang Y, Cui X et al.. “Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.” Frontiers in pharmacology (2026). PMID: 42394981 ↗
L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[76]
Sanchez-Rangel E, Inzucchi SE. “Metformin: clinical use in type 2 diabetes.” Diabetologia (2017). PMID: 28770321 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[77]
Davies MJ, Aroda VR, Collins BS et al.. “Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetologia (2022). PMID: 36151309 ↗
L1REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[78]
Vergès B. “Pathophysiology of diabetic dyslipidaemia: where are we?” Diabetologia (2015). PMID: 25725623 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[79]
Sun WT, Liu RX, Jiang YH et al.. “Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.” Diabetes, obesity & metabolism (2026). PMID: 42426564 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[80]
Caruso P, Di Martino N, Longo M et al.. “Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies.” Cardiovascular diabetology (2026). PMID: 42410649 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[81]
Li R, Zhao X, Shen J et al.. “Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies.” Preventive medicine reports (2026). PMID: 42381894 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[82]
Soliman AT, Alyafei F, Khalil A et al.. “GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.” Diabetes research and clinical practice (2026). PMID: 42365860 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[83]
Mohammadi D, Sadeghirad B, Rasouli MA et al.. “Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials.” Diabetology & metabolic syndrome (2026). PMID: 42365335 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[84]
Kautzky-Willer A, Harreiter J, Pacini G. “Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus.” Endocrine reviews (2016). PMID: 27159875 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[85]
Cornier MA, Dabelea D, Hernandez TL et al.. “The metabolic syndrome.” Endocrine reviews (2008). PMID: 18971485 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[86]
Kodl CT, Seaquist ER. “Cognitive dysfunction and diabetes mellitus.” Endocrine reviews (2008). PMID: 18436709 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[87]
Donath MY, Meier DT, Böni-Schnetzler M. “Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.” Endocrine reviews (2019). PMID: 31127805 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[88]
Patti ME, Corvera S. “The role of mitochondria in the pathogenesis of type 2 diabetes.” Endocrine reviews (2010). PMID: 20156986 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
[89]
Ussher JR, Drucker DJ. “Cardiovascular biology of the incretin system.” Endocrine reviews (2012). PMID: 22323472 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[90]
Meijnikman AS, Gerdes VE, Nieuwdorp M et al.. “Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.” Endocrine reviews (2018). PMID: 29309555 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature
[91]
Abdul-Ghani MA, Norton L, Defronzo RA. “Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.” Endocrine reviews (2011). PMID: 21606218 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[92]
Pal K, Eastwood SV, Michie S et al.. “Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23543567 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[93]
Kanie T, Mizuno A, Takaoka Y et al.. “Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.” The Cochrane database of systematic reviews (2021). PMID: 34693515 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[94]
El Dib R, Gameiro OL, Ogata MS et al.. “Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.” The Cochrane database of systematic reviews (2015). PMID: 26020622 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[95]
Richter B, Bandeira-Echtler E, Bergerhoff K et al.. “Rosiglitazone for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17636824 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors
[96]
Richter B, Bandeira-Echtler E, Bergerhoff K et al.. “Pioglitazone for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2006). PMID: 17054272 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[97]
Beletate V, El Dib RP, Atallah AN. “Zinc supplementation for the prevention of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17253560 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[98]
Valentine N, Van de Laar FA, van Driel ML. “Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 23152231 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[99]
Osman AA, Tayeb BA, Metzendorf MI et al.. “Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis.” The Cochrane database of systematic reviews (2025). PMID: 40237224 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature
[100]
Pitta FG, Lima EG, Tavares CAM et al.. “Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial.” Diabetes care (2025). PMID: 40233024 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[101]
Ye W, Xu L, Ye Y et al.. “Efficacy and Safety of Meal Replacement in Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37192345 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[102]
Barbarawi M, Zayed Y, Barbarawi O et al.. “Effect of Vitamin D Supplementation on the Incidence of Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32491181 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[103]
Gershkowitz BD, Hillert CJ, Crotty BH. “Digital Coaching Strategies to Facilitate Behavioral Change in Type 2 Diabetes: A Systematic Review.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33206975 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
[104]
Llamosas-Falcón L, Rehm J, Bright S et al.. “The Relationship Between Alcohol Consumption, BMI, and Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis.” Diabetes care (2023). PMID: 37890103 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[105]
Cummings DE, Cohen RV. “Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI <35 kg/m2.” Diabetes care (2016). PMID: 27222550 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[106]
Inagaki N, Onouchi H, Sano H et al.. “SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.” The lancet. Diabetes & endocrinology (2013). PMID: 24622716 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[107]
Marso SP, Daniels GH, Brown-Frandsen K et al.. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2016). PMID: 27295427 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[108]
Duckworth W, Abraira C, Moritz T et al.. “Glucose control and vascular complications in veterans with type 2 diabetes.” The New England journal of medicine (2008). PMID: 19092145 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[109]
Steg PG, Bhatt DL, Simon T et al.. “Ticagrelor in Patients with Stable Coronary Disease and Diabetes.” The New England journal of medicine (2019). PMID: 31475798 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors
[110]
Gaede P, Lund-Andersen H, Parving HH et al.. “Effect of a multifactorial intervention on mortality in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18256393 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors
[111]
DeFronzo RA, Tripathy D, Schwenke DC et al.. “Pioglitazone for diabetes prevention in impaired glucose tolerance.” The New England journal of medicine (2011). PMID: 21428766 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[112]
Bosch J, Gerstein HC, Dagenais GR et al.. “n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.” The New England journal of medicine (2012). PMID: 22686415 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors
[113]
Yu J, Kim B, Han K et al.. “Diabetes Progression and Its Impact on Kidney Cancer Risk: Insights From a Longitudinal Korean Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40459059 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors
[114]
Carey IM, Critchley JA, DeWilde S et al.. “Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study.” Diabetes care (2018). PMID: 29330152 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[115]
Anagnostis P, Christou K, Artzouchaltzi AM et al.. “Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis.” European journal of endocrinology (2019). PMID: 30400047 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[116]
Wang B, Xu D, Jing Z et al.. “Effect of long-term exposure to air pollution on type 2 diabetes mellitus risk: a systemic review and meta-analysis of cohort studies.” European journal of endocrinology (2014). PMID: 25298376 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[117]
Kawamori R, Tajima N, Iwamoto Y et al.. “Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.” Lancet (London, England) (2009). PMID: 19395079 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
[118]
Rajamani K, Colman PG, Li LP et al.. “Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.” Lancet (London, England) (2009). PMID: 19465233 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[119]
Zinman B, Harris SB, Neuman J et al.. “Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.” Lancet (London, England) (2010). PMID: 20605202 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[120]
Bretzel RG, Nuber U, Landgraf W et al.. “Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.” Lancet (London, England) (2008). PMID: 18374840 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors
[121]
Exalto LG, Biessels GJ, Karter AJ et al.. “Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study.” The lancet. Diabetes & endocrinology (2013). PMID: 24622366 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae
[122]
Kramer CK, Campbell S, Retnakaran R. “Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis.” Diabetologia (2019). PMID: 30843102 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[123]
Smith AD, Crippa A, Woodcock J et al.. “Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies.” Diabetologia (2016). PMID: 27747395 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[124]
Knol MJ, Twisk JW, Beekman AT et al.. “Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis.” Diabetologia (2006). PMID: 16520921 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
[125]
Mikłosz A, Chabowski A. “Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36916961 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[126]
Zhao H, Zhang B, Zhuo L et al.. “Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation.” Diabetes care (2025). PMID: 40131448 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[127]
Jun JE, Jee JH, Bae JC et al.. “Association Between Changes in Thyroid Hormones and Incident Type 2 Diabetes: A Seven-Year Longitudinal Study.” Thyroid : official journal of the American Thyroid Association (2016). PMID: 27809684 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[128]
Galazis N, Afxentiou T, Xenophontos M et al.. “Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome.” European journal of endocrinology (2013). PMID: 23093701 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[129]
Anagnostis P, Majeed A, Johnston DG et al.. “Cardiovascular risk in women with type 2 diabetes mellitus and prediabetes: is it indeed higher than men?” European journal of endocrinology (2014). PMID: 25117464 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
[130]
Ittermann T, Markus MR, Schipf S et al.. “Metformin inhibits goitrogenous effects of type 2 diabetes.” European journal of endocrinology (2013). PMID: 23572084 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[131]
Kautzky-Willer A, Leutner M, Harreiter J. “Sex differences in type 2 diabetes.” Diabetologia (2023). PMID: 36897358 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[132]
Gao L, Ye G, Liu C et al.. “Prevalence and risk factors of hyperuricemia and gout in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42422434 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[133]
Michels D, Walter C, Grathwohl-Karl A et al.. “Type 2 diabetes prevention programs at the community and municipal level: a scoping review of controlled intervention studies.” BMC public health (2026). PMID: 42387346 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[134]
Bray GA, Heisel WE, Afshin A et al.. “The Science of Obesity Management: An Endocrine Society Scientific Statement.” Endocrine reviews (2018). PMID: 29518206 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[135]
Di Pino A, DeFronzo RA. “Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.” Endocrine reviews (2019). PMID: 31050706 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae
[136]
Randeva HS, Tan BK, Weickert MO et al.. “Cardiometabolic aspects of the polycystic ovary syndrome.” Endocrine reviews (2012). PMID: 22829562 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[137]
Gupta N, Goel K, Shah P et al.. “Childhood obesity in developing countries: epidemiology, determinants, and prevention.” Endocrine reviews (2012). PMID: 22240243 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History and Prevention
[138]
Peer N, Balakrishna Y, Durao S. “Screening for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 32470201 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[139]
Naude CE, Brand A, Schoonees A et al.. “Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk.” The Cochrane database of systematic reviews (2022). PMID: 35088407 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[140]
Motuhifonua SK, Lin L, Alsweiler J et al.. “Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.” The Cochrane database of systematic reviews (2023). PMID: 36790138 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[141]
Astavans A, Baughman D, Mathioudakis N. “Long-Term Major Adverse Cardiovascular and Cerebrovascular Event Risk in Adult-Onset Type 1 Versus Type 2 Diabetes: A Propensity-Matched Cohort Study.” European journal of preventive cardiology (2026). PMID: 42429688 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[142]
Wang M, Tipping O, Liu B et al.. “New-Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank.” International journal of cancer (2026). PMID: 42424092 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[143]
Gu L, Yang J, Shen J et al.. “Biological aging and the incidence and progression of diabetic retinopathy and kidney disease in type 2 diabetes mellitus: A prospective cohort study.” Diabetes research and clinical practice (2026). PMID: 42419488 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae
[144]
Park SM, Ko AJ, Lim JH et al.. “Income level and the risk of incident dementia among adults aged ≥50 with newly diagnosed type 2 diabetes: a population-based cohort study using the NHIS-Senior database in South Korea.” BMJ open (2026). PMID: 42409396 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[145]
Lee SH, Lee KS, Lee JY et al.. “Impact of gestational diabetes on future diabetic retinopathy and microvascular complications: a nationwide cohort study.” BMC medicine (2026). PMID: 42399945 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae
[146]
Katznelson L. “Approach to the patient with persistent acromegaly after pituitary surgery.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20823464 ↗
L5CASE_REPORTCited in: Clinical Presentation
[147]
Tsang VHM, McGrath RT, Clifton-Bligh RJ et al.. “Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31265074 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[148]
Xin H, Fu Y, Feng M et al.. “Altered Intrinsic Brain Activity Related to Neurologic and Motor Dysfunction in Diabetic Peripheral Neuropathy Patients.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36333998 ↗
L3OTHERCited in: Clinical Presentation
[149]
Xin A, Mizukami H, Inaba W et al.. “Pancreas Atrophy and Islet Amyloid Deposition in Patients With Elderly-Onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28505316 ↗
L3OTHERCited in: Clinical Presentation
[150]
Gong S, Guo J, Han X et al.. “Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28324025 ↗
L3OTHERCited in: Clinical Presentation
[151]
Smith RJ, Nathan DM, Arslanian SA et al.. “Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20194712 ↗
L5OTHERCited in: Clinical Presentation
[152]
Sahu RP, Aggarwal A, Zaidi G et al.. “Etiology of early-onset type 2 diabetes in Indians: islet autoimmunity and mutations in hepatocyte nuclear factor 1alpha and mitochondrial gene.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17440016 ↗
L3OTHERCited in: Clinical Presentation
[153]
Eldor R, Klieger Y, Sade-Feldman M et al.. “CD247, a novel T cell-derived diagnostic and prognostic biomarker for detecting disease progression and severity in patients with type 2 diabetes.” Diabetes care (2014). PMID: 25368105 ↗
L3OTHERCited in: Clinical Presentation
[154]
Alsaigh T, Dhaliwal G, Fukaya E et al.. “An Alternate Explanation.” The New England journal of medicine (2023). PMID: 37018496 ↗
L4CASE_REPORTCited in: Clinical Presentation
[155]
Grossmann M, Anawalt BD, Yeap BB. “Testosterone therapy in older men: clinical implications of recent landmark trials.” European journal of endocrinology (2024). PMID: 38917356 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[156]
Palmieri S, Morelli V, Polledri E et al.. “The role of salivary cortisol measured by liquid chromatography-tandem mass spectrometry in the diagnosis of subclinical hypercortisolism.” European journal of endocrinology (2013). PMID: 23211572 ↗
L2OTHERCited in: Clinical Presentation
[157]
Ziegler TR. “Parenteral nutrition in the critically ill patient.” The New England journal of medicine (2009). PMID: 19741230 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[158]
Miller RA, Birnbaum MJ. “Glucagon: acute actions on hepatic metabolism.” Diabetologia (2016). PMID: 27115415 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management and Endocrine Emergencies
[159]
Bonora E, Corrao G, Bagnardi V et al.. “Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus.” Diabetologia (2006). PMID: 16532323 ↗
L2OTHERCited in: Clinical Presentation
[160]
Labad J, Price JF, Strachan MW et al.. “Symptoms of depression but not anxiety are associated with central obesity and cardiovascular disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.” Diabetologia (2009). PMID: 20012009 ↗
L2OTHERCited in: Clinical Presentation
[161]
Visser ME, Kropman E, Kranendonk ME et al.. “Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).” Diabetologia (2011). PMID: 21479595 ↗
L4OTHERCited in: Clinical Presentation
[162]
Mikkelsen R, Larsen JB, Smidt K. “Association between Sex and Platelet Function in Patients with Diabetes Mellitus Type II: A Systematic Review.” Seminars in thrombosis and hemostasis (2026). PMID: 42263761 ↗
L2SR_OBSCited in: Clinical Presentation, History and Evolution of Treatment
[163]
Mirmosayyeb O, Shaygannejad A, Vaheb S et al.. “Type 2 diabetes mellitus in people with multiple sclerosis: a systematic review and meta-analysis.” Acta neurologica Belgica (2026). PMID: 41975171 ↗
L2SR_OBSCited in: Clinical Presentation
[164]
Paz-Pacheco E, Oliva RV, Acuin CS et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Renal, Metabolic, Nutritional, and Endocrine Disorders.” Acta medica Philippina (2026). PMID: 42382928 ↗
L1GUIDELINECited in: Clinical Presentation, Severity, Staging and Risk Stratification
[165]
Xiang Y, Fan B, Liu B. “Abdominal wall abscess due to Mycolicibacterium neworleansense: a case report.” BMC infectious diseases (2026). PMID: 42380938 ↗
L4CASE_REPORTCited in: Clinical Presentation
[166]
Liang H, Mao ZF, Huang JY et al.. “Case Report: Moxibustion-induced burns leading to disseminated methicillin-resistant Staphylococcus aureus infection in a patient with type 2 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42272806 ↗
L4CASE_REPORTCited in: Clinical Presentation
[167]
Xu Y, Wang L, Li H et al.. “Mycobacterium abscessus bacteremia complicated by sepsis and septic shock in a patient with multiple comorbidities: a case report.” Frontiers in immunology (2026). PMID: 42183259 ↗
L4CASE_REPORTCited in: Clinical Presentation
[168]
Bai H, Yu J, Wang T et al.. “Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.” Frontiers in endocrinology (2026). PMID: 42137361 ↗
L4CASE_REPORTCited in: Clinical Presentation
[169]
Uhl S, Choure A, Rouse B et al.. “Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37987208 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[170]
Fassnacht M, Tsagarakis S, Terzolo M et al.. “European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.” European journal of endocrinology (2023). PMID: 37318239 ↗
L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[171]
Kramer CK, Zinman B, Feig DS et al.. “Effect of Time-Restricted Eating on β-Cell Function in Adults With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39193706 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[172]
Robledo KP, Marschner IC, Handelsman DJ et al.. “Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trial.” European journal of endocrinology (2023). PMID: 37406250 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[173]
Grey A, Beckley V, Doyle A et al.. “Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial.” European journal of endocrinology (2012). PMID: 22408124 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[174]
Flachs Madsen LR, Gerdøe-Kristensen S, Lauenborg J et al.. “Long-Term Follow-Up on Morbidity Among Women With a History of Gestational Diabetes Mellitus: A Systematic Review.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35763540 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[175]
Hespanhol LC, Agarwal S, Carvalhal G et al.. “Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.” Diabetes care (2026). PMID: 41940799 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[176]
Qiang J, Pathmaraj M, Lo T et al.. “The Effectiveness of Diabetes Prevention Programs Delivered in Primary Care for Individuals With Prediabetes or at Risk of Developing Type 2 Diabetes: A Systematic Review and Meta-analysis.” Diabetes care (2026). PMID: 42030121 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[177]
Gyldenkerne C, Kahlert J, Olesen KKW et al.. “Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study.” Diabetes care (2022). PMID: 35876649 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[178]
Aslam AA, Baksh RA, Pape SE et al.. “Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records.” Diabetes care (2022). PMID: 36178378 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[179]
Andrews RC, Cooper AR, Montgomery AA et al.. “Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial.” Lancet (London, England) (2011). PMID: 21705068 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[180]
Aschner P, Chan J, Owens DR et al.. “Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.” Lancet (London, England) (2012). PMID: 22683131 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[181]
Thomsen MN, Skytte MJ, Samkani A et al.. “Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial.” Diabetologia (2022). PMID: 34993571 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[182]
Sanchez-Rangel E, Gunawan F, Jiang L et al.. “Reversibility of brain glucose kinetics in type 2 diabetes mellitus.” Diabetologia (2022). PMID: 35247067 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[183]
Nanayakkara N, Curtis AJ, Heritier S et al.. “Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses.” Diabetologia (2020). PMID: 33313987 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[184]
Yapanis M, James S, Craig ME et al.. “Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35094087 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[185]
Qi L, Chen Y. “Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36374935 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment, Prognosis, Natural History and Prevention
[186]
Fiorentino TV, Marini MA, Succurro E et al.. “One-Hour Postload Hyperglycemia: Implications for Prediction and Prevention of Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30020454 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[187]
Li K, Liao X, Wang K et al.. “Myonectin Predicts the Development of Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29161407 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[188]
Sakhaee K, Maalouf NM, Sinnott B. “Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22466339 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[189]
Galvez-Fernandez M, Powers M, Grau-Perez M et al.. “Urinary Zinc and Incident Type 2 Diabetes: Prospective Evidence From the Strong Heart Study.” Diabetes care (2022). PMID: 36134919 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[190]
Li Y, Tian J, Hou T et al.. “Association Between Age at Diabetes Diagnosis and Subsequent Incidence of Cancer: A Longitudinal Population-Based Cohort.” Diabetes care (2024). PMID: 38237119 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[191]
Bril F, Cusi K. “Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.” Diabetes care (2017). PMID: 28223446 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
[192]
Steven S, Hollingsworth KG, Small PK et al.. “Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes.” Diabetes care (2015). PMID: 26628414 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[193]
Brinkhues S, Dukers-Muijrers NHTM, Hoebe CJPA et al.. “Social Network Characteristics Are Associated With Type 2 Diabetes Complications: The Maastricht Study.” Diabetes care (2018). PMID: 29907582 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[194]
Deetman PE, Kwakernaak AJ, Bakker SJ et al.. “Low-normal free thyroxine confers decreased serum bilirubin in type 2 diabetes mellitus.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23638994 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae
[195]
Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D et al.. “METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes.” European journal of endocrinology (2018). PMID: 29535168 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[196]
Andersen M, Glintborg D. “Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?” European journal of endocrinology (2018). PMID: 29921567 ↗
L5OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[197]
Vrbikova J, Hill M, Bendlova B et al.. “Incretin levels in polycystic ovary syndrome.” European journal of endocrinology (2008). PMID: 18511472 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[198]
de Araújo IM, Salmon CE, Nahas AK et al.. “Marrow adipose tissue spectrum in obesity and type 2 diabetes mellitus.” European journal of endocrinology (2016). PMID: 27707768 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[199]
Panidis D, Tziomalos K, Chatzis P et al.. “Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.” European journal of endocrinology (2013). PMID: 23109645 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[200]
Hanslik G, Wallaschofski H, Dietz A et al.. “Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry.” European journal of endocrinology (2015). PMID: 26311088 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[201]
Gustafson D, DiStefano PV, Wang XF et al.. “Circulating small extracellular vesicles mediate vascular hyperpermeability in diabetes.” Diabetologia (2024). PMID: 38489029 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[202]
Jarosinski MA, Dhayalan B, Rege N et al.. “'Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues.” Diabetologia (2021). PMID: 33710398 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies
[203]
Gupta S, Eavey RD, Wang M et al.. “Type 2 diabetes and the risk of incident hearing loss.” Diabetologia (2018). PMID: 30402776 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[204]
Abd-Alrazaq A, Mohamed SP, Alajlani M et al.. “Performance of AI in Predicting the Progression of Gestational Diabetes to Type 2 Diabetes: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2026). PMID: 42424585 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History and Prevention
[205]
Simpson TC, Clarkson JE, Worthington HV et al.. “Treatment of periodontitis for glycaemic control in people with diabetes mellitus.” The Cochrane database of systematic reviews (2022). PMID: 35420698 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[206]
Cashmore BA, Cooper TE, Evangelidis NM et al.. “Education programmes for people with chronic kidney disease and diabetes.” The Cochrane database of systematic reviews (2024). PMID: 39171639 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[207]
Jeyaraman MM, Al-Yousif NSH, Singh Mann A et al.. “Resveratrol for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 31978258 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[208]
Nield L, Moore HJ, Hooper L et al.. “Dietary advice for treatment of type 2 diabetes mellitus in adults.” The Cochrane database of systematic reviews (2007). PMID: 17636747 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[209]
Hemmingsen B, Krogh J, Metzendorf MI et al.. “Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2016). PMID: 27101360 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[210]
Callaghan BC, Little AA, Feldman EL et al.. “Enhanced glucose control for preventing and treating diabetic neuropathy.” The Cochrane database of systematic reviews (2012). PMID: 22696371 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[211]
Malanda UL, Welschen LM, Riphagen II et al.. “Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.” The Cochrane database of systematic reviews (2012). PMID: 22258959 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[212]
Middleton P, Crowther CA. “Reminder systems for women with previous gestational diabetes mellitus to increase uptake of testing for type 2 diabetes or impaired glucose tolerance.” The Cochrane database of systematic reviews (2014). PMID: 24638998 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[213]
Pan SY, Weng CH, Sheen YJ et al.. “Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.” Ophthalmology science (2026). PMID: 42383218 ↗
L3COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment
[214]
Lai SW, Liao KF. “Herpes zoster as a potential clinical marker of undiagnosed Type 2 diabetes in older adults: a retrospective cohort study.” Family practice (2026). PMID: 42348717 ↗
L3COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[215]
Singhai A, Meena R, Joshi R et al.. “Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis.” The Indian journal of medical research (2026). PMID: 42397829 ↗
L4SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[216]
Wang J, Chen L, Chen X et al.. “Tracing the clinicodermoscopic and histopathological evolution of acquired reactive perforating collagenosis: a case report.” Frontiers in medicine (2026). PMID: 42383033 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[217]
Prasad AV, Mathai TS, Balamuralikrishna PTS et al.. “Utility of Pancreatic Perivascular Adipose Tissue as a CT Imaging Biomarker for Diagnosing Type 2 Diabetes.” Diabetes (2026). PMID: 42423517 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
[218]
DeBoer MD, Filipp SL, Gurka MJ. “Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program.” Diabetes care (2018). PMID: 30275282 ↗
L2RCTCited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[219]
Zhang J, Tam WWS, Lu J et al.. “Cognitive Risk Stratification Score in Middle-aged and Older Adults With Type 2 Diabetes: A Cross-Sectional Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39901828 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification
[220]
Fang F, Lai MY, Huang JJ et al.. “Compensatory Hippocampal Connectivity in Young Adults With Early-Stage Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30817818 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification
[221]
Kalavalapalli S, Leiva EG, Lomonaco R et al.. “Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36378995 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification
[222]
Strickland LR, Guo F, Lok K et al.. “Type 2 diabetes with partial lipodystrophy of the limbs: a new lipodystrophy phenotype.” Diabetes care (2013). PMID: 23423695 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification
[223]
Lomonaco R, Bril F, Portillo-Sanchez P et al.. “Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.” Diabetes care (2016). PMID: 26861926 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification
[224]
Ortiz-Lopez C, Lomonaco R, Orsak B et al.. “Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).” Diabetes care (2012). PMID: 22374640 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification
[225]
Hulten E, Bittencourt MS, O'Leary D et al.. “Cardiometabolic risk is associated with atherosclerotic burden and prognosis: results from the partners coronary computed tomography angiography registry.” Diabetes care (2013). PMID: 24130364 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification
[226]
Segar MW, Vaduganathan M, Patel KV et al.. “Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score.” Diabetes care (2019). PMID: 31519694 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification
[227]
Park SE, Kim WJ, Park SW et al.. “High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria.” European journal of endocrinology (2013). PMID: 23144053 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification
[228]
Lerchbaum E, Schwetz V, Giuliani A et al.. “Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women.” European journal of endocrinology (2014). PMID: 24591551 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification
[229]
Oltmanns KM, Dodt B, Schultes B et al.. “Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients.” European journal of endocrinology (2006). PMID: 16452548 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification
[230]
Zhou Y, Hu L, Zhuang R et al.. “METRNL represses beta-to-alpha cell trans-differentiation to maintain beta cell function under diabetic metabolic stress in mice.” Diabetologia (2025). PMID: 40495021 ↗
L5OTHERCited in: Severity, Staging and Risk Stratification
[231]
Xepapadaki E, Nikdima I, Sagiadinou EC et al.. “HDL and type 2 diabetes: the chicken or the egg?” Diabetologia (2021). PMID: 34255113 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[232]
Highton PJ, Funnell MP, Gupta P et al.. “Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes.” Diabetologia (2025). PMID: 41315090 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification
[233]
Yang Y, Wang K. “Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.” Frontiers in pharmacology (2026). PMID: 42389271 ↗
L5SR_OBSCited in: Severity, Staging and Risk Stratification
[234]
Alyas JT, Nielsen SF, Buus NH. “Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics.” Journal of hypertension (2026). PMID: 42359837 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification
[235]
Rosenfield RL. “The Search for the Causes of Common Hyperandrogenism, 1965 to Circa 2015.” Endocrine reviews (2024). PMID: 38457123 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification, History and Evolution of Treatment
[236]
Yan C, Zhao Y, Zhang W et al.. “Baseline levels and dynamic trajectories of fasting C peptide to blood glucose ratio predict the risk of combined vascular damage in type 2 diabetes: a longitudinal cohort study.” Diabetes research and clinical practice (2026). PMID: 42379426 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification
[237]
Hussain SI, Jalal AA, Adnan Z et al.. “Efficacy and Safety of Pioglitazone Added to Metformin and SGLT2 Inhibitors in Type 2 Diabetes: An Updated Systematic Review and Meta-analysis.” The Annals of pharmacotherapy (2026). PMID: 42365460 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification
[238]
Cabaluna ITG, Sulit MVV, Infantado-Alejandro MAJ et al.. “2021 Clinical Practice Guidelines on Periodic Health Examination.” Acta medica Philippina (2026). PMID: 42382929 ↗
L1GUIDELINECited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies
[239]
Strojek K, Raz I, Jermendy G et al.. “Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26595100 ↗
L2RCTCited in: Acute Management and Endocrine Emergencies
[240]
Stähli BE, Nozza A, Schrieks IC et al.. “Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29659887 ↗
L2RCTCited in: Acute Management and Endocrine Emergencies
[241]
Vestergaard ET, Jessen N, Møller N et al.. “Unacylated Ghrelin Does Not Acutely Affect Substrate Metabolism or Insulin Sensitivity in Men With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30722063 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies
[242]
D'Alessio DA, Denney AM, Hermiller LM et al.. “Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18957505 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies
[243]
Umpierrez GE, Smiley D, Jacobs S et al.. “Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery).” Diabetes care (2011). PMID: 21228246 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[244]
Novak V, Milberg W, Hao Y et al.. “Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes.” Diabetes care (2013). PMID: 24101698 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment
[245]
Daniele G, Xiong J, Solis-Herrera C et al.. “Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.” Diabetes care (2016). PMID: 27561923 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment
[246]
Schrieks IC, Nozza A, Stähli BE et al.. “Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.” Diabetes care (2018). PMID: 29903845 ↗
L2RCTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[247]
Stirban A, Kotsi P, Franke K et al.. “Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins.” Diabetes care (2012). PMID: 23238657 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies
[248]
Steven S, Hollingsworth KG, Al-Mrabeh A et al.. “Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders.” Diabetes care (2016). PMID: 27002059 ↗
L4TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies
[249]
Bhatt DL, Szarek M, Steg PG et al.. “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.” The New England journal of medicine (2020). PMID: 33200892 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[250]
Bhatt DL, Szarek M, Pitt B et al.. “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2020). PMID: 33200891 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[251]
Scirica BM, Bhatt DL, Braunwald E et al.. “Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.” The New England journal of medicine (2013). PMID: 23992601 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[252]
Zhong VW, Juhaeri J, Mayer-Davis EJ. “Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2018). PMID: 29386248 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies
[253]
Elbalshy MM, Reynolds AN, Mete E et al.. “Gelatinisation and milling whole-wheat increases postprandial blood glucose: randomised crossover study of adults with type 2 diabetes.” Diabetologia (2021). PMID: 33677626 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies
[254]
Chang LY, Liao HW, Chen JY et al.. “Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39535770 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[255]
Sereg M, Szappanos A, Toke J et al.. “Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study.” European journal of endocrinology (2009). PMID: 19174533 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies
[256]
Ryskjaer J, Deacon CF, Carr RD et al.. “Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.” European journal of endocrinology (2006). PMID: 16914604 ↗
L4OTHERCited in: Acute Management and Endocrine Emergencies
[257]
Pinhas-Hamiel O, Zeitler P. “Acute and chronic complications of type 2 diabetes mellitus in children and adolescents.” Lancet (London, England) (2007). PMID: 17531891 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[258]
Htoo PT, Tesfaye H, Schneeweiss S et al.. “Effectiveness and safety of empagliflozin: final results from the EMPRISE study.” Diabetologia (2024). PMID: 38509341 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae
[259]
Home P. “Cardiovascular outcome trials of glucose-lowering medications: an update.” Diabetologia (2019). PMID: 30607467 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies
[260]
Assogba FG, Couchoud C, Hannedouche T et al.. “Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011.” Diabetologia (2014). PMID: 24496924 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies
[261]
Cline GW, Naganawa M, Chen L et al.. “Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.” Diabetologia (2018). PMID: 29721633 ↗
L4OTHERCited in: Acute Management and Endocrine Emergencies
[262]
Vinué Á, Navarro J, Herrero-Cervera A et al.. “The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.” Diabetologia (2017). PMID: 28608285 ↗
L5OTHERCited in: Acute Management and Endocrine Emergencies
[263]
Rodrigues SN, Guterres BV, Carvalho MTX et al.. “Effects of a Synchronous Telehealth Exercise Program on Clinical, Functional, and Psychosocial Outcomes in Individuals with Type 2 Diabetes Mellitus (RED Study): A Randomized Clinical Trial.” International journal of environmental research and public health (2026). PMID: 42354303 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, History and Evolution of Treatment
[264]
Suda M, Paul KH, Tripathi U et al.. “Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction.” Endocrine reviews (2024). PMID: 38500373 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[265]
Dodd JM, Grivell RM, Deussen AR et al.. “Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.” The Cochrane database of systematic reviews (2018). PMID: 30039871 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[266]
Yang S, Ma L, Zeng J et al.. “Trajectory models of serum creatinine and 28-day mortality in critically ill patients with sepsis complicated by type 2 diabetes mellitus: a cohort study.” Frontiers in endocrinology (2026). PMID: 42416900 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[267]
Jung K, Kim GA, Woo J et al.. “Ursodeoxycholic Acid and Long COVID in Steatotic Liver Disease: A Nationwide Cohort Study.” Clinical and molecular hepatology (2026). PMID: 42263781 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies
[268]
Ngiam JN, Loy EX, Koh MCY et al.. “Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study.” Infectious diseases and therapy (2026). PMID: 42236640 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies
[269]
Tang L, He Y, Qiao Z et al.. “Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.” Frontiers in immunology (2026). PMID: 42344901 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies
[270]
Kang YM, Giugliano RP, Ran X et al.. “Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.” Diabetes care (2025). PMID: 40544474 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[271]
Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R et al.. “Curcumin extract for prevention of type 2 diabetes.” Diabetes care (2012). PMID: 22773702 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History and Prevention
[272]
Stomby A, Otten J, Ryberg M et al.. “Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32069218 ↗
L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[273]
Whipple MO, Pinto AJ, Abushamat LA et al.. “Sex Differences in Physical Activity Among Individuals With Type 2 Diabetes Across the Life Span: A Systematic Review and Meta-analysis.” Diabetes care (2022). PMID: 36044665 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[274]
Weber MA, Mansfield TA, Cain VA et al.. “Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.” The lancet. Diabetes & endocrinology (2015). PMID: 26620248 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[275]
Perkovic V, Jardine MJ, Neal B et al.. “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.” The New England journal of medicine (2019). PMID: 30990260 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[276]
Holman RR, Paul SK, Bethel MA et al.. “10-year follow-up of intensive glucose control in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18784090 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[277]
Cushman WC, Evans GW, Byington RP et al.. “Effects of intensive blood-pressure control in type 2 diabetes mellitus.” The New England journal of medicine (2010). PMID: 20228401 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[278]
Ginsberg HN, Elam MB, Lovato LC et al.. “Effects of combination lipid therapy in type 2 diabetes mellitus.” The New England journal of medicine (2010). PMID: 20228404 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[279]
Santi D, Giannetta E, Isidori AM et al.. “Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.” European journal of endocrinology (2014). PMID: 25277671 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[280]
Patel A, MacMahon S, Chalmers J et al.. “Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17765963 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae
[281]
Garber A, Henry R, Ratner R et al.. “Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.” Lancet (London, England) (2008). PMID: 18819705 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[282]
Garber AJ, King AB, Del Prato S et al.. “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.” Lancet (London, England) (2012). PMID: 22521072 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment
[283]
Rosenstock J, Lorber DL, Gnudi L et al.. “Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.” Lancet (London, England) (2010). PMID: 20609970 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[284]
Muir CA, Wittert GA, Handelsman DJ. “Approach to the Patient: Low Testosterone Concentrations in Men With Obesity.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40052430 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[285]
Chee YJ, Acharyya S, Liew H et al.. “First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.” Diabetes, obesity & metabolism (2026). PMID: 42396722 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[286]
Rieg T, Vallon V. “Development of SGLT1 and SGLT2 inhibitors.” Diabetologia (2018). PMID: 30132033 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[287]
Ghezzi C, Loo DDF, Wright EM. “Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.” Diabetologia (2018). PMID: 30132032 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[288]
Schrauwen P, van Marken Lichtenbelt WD. “Combatting type 2 diabetes by turning up the heat.” Diabetologia (2016). PMID: 27591854 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[289]
Forrestel AC, Miedlich SU, Yurcheshen M et al.. “Chronomedicine and type 2 diabetes: shining some light on melatonin.” Diabetologia (2016). PMID: 27981356 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[290]
Zhang Q, Ouyang Y, He S et al.. “The efficacy and safety of Chaihu guizhi ganjiang tang for type 2 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42428496 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[291]
Jais A, Brüning JC. “Arcuate Nucleus-Dependent Regulation of Metabolism-Pathways to Obesity and Diabetes Mellitus.” Endocrine reviews (2022). PMID: 34490882 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[292]
Gilbert MP, Pratley RE. “The impact of diabetes and diabetes medications on bone health.” Endocrine reviews (2015). PMID: 25738213 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[293]
Leach MJ, Kumar S. “Cinnamon for diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22972104 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae
[294]
Pattanittum P, Ngamjarus C, Buttramee F et al.. “Roselle for hypertension in adults.” The Cochrane database of systematic reviews (2021). PMID: 34837382 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History and Prevention
[295]
Ooi CP, Loke SC. “Colesevelam for type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 23235674 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[296]
Saboo B, Sabharwal M, Gharia M et al.. “App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study.” JMIR diabetes (2026). PMID: 42418692 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[297]
Huang R, Wang B. “Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.” The Journal of international medical research (2026). PMID: 42424036 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[298]
Tian R, Zhou X, Pan J et al.. “Activation of Nrf2 signaling and suppression of oxidative stress-induced neuronal apoptosis: mechanisms for baicalin capsules relieving diabetic encephalopathy.” Frontiers in pharmacology (2026). PMID: 42434129 ↗
L5OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
[299]
Zhou Y, Huang Y, Ji X et al.. “Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31822895 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention
[300]
Errazuriz I, Dube S, Slama M et al.. “Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28323952 ↗
L1RCTCited in: History and Evolution of Treatment
[301]
Deng X, Zhang C, Wang P et al.. “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35397165 ↗
L1RCTCited in: History and Evolution of Treatment
[302]
Bokhari S, Plummer E, Emmerson P et al.. “Glucose counterregulation in advanced type 2 diabetes: effect of β-adrenergic blockade.” Diabetes care (2014). PMID: 25092686 ↗
L2RCTCited in: History and Evolution of Treatment
[303]
Hoogendoorn CJ, Krause-Steinrauf H, Uschner D et al.. “Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).” Diabetes care (2024). PMID: 38227900 ↗
L2RCTCited in: History and Evolution of Treatment
[304]
Ajjan RA, Hensor EMA, Del Galdo F et al.. “Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.” European journal of endocrinology (2022). PMID: 35113805 ↗
L1RCTCited in: History and Evolution of Treatment
[305]
Van Raalte DH, van Genugten RE, Eliasson B et al.. “The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.” European journal of endocrinology (2014). PMID: 24421302 ↗
L1RCTCited in: History and Evolution of Treatment
[306]
Maxwell JD, Carter HH, Hellsten Y et al.. “Seven-day remote ischaemic preconditioning improves endothelial function in patients with type 2 diabetes mellitus: a randomised pilot study.” European journal of endocrinology (2019). PMID: 31614332 ↗
L1RCTCited in: History and Evolution of Treatment
[307]
Park JS, Cho MH, Nam JS et al.. “Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.” European journal of endocrinology (2010). PMID: 20961967 ↗
L2RCTCited in: History and Evolution of Treatment
[308]
Fang FS, Gong YP, Li CL et al.. “Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.” European journal of endocrinology (2014). PMID: 24694876 ↗
L1RCTCited in: History and Evolution of Treatment
[309]
Tuomilehto J, Lindström J, Eriksson JG et al.. “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.” The New England journal of medicine (2001). PMID: 11333990 ↗
L1RCTCited in: History and Evolution of Treatment
[310]
Zhao G, Bhatia D, Jung F et al.. “Risk of type 2 diabetes mellitus in women with prior hypertensive disorders of pregnancy: a systematic review and meta-analysis.” Diabetologia (2021). PMID: 33409572 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[311]
Han LY, Wu QH, Jiao ML et al.. “Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, -11377C>G, -11391G>A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2011). PMID: 21638131 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[312]
Keech A, Simes RJ, Barter P et al.. “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.” Lancet (London, England) (2005). PMID: 16310551 ↗
L1RCTCited in: History and Evolution of Treatment
[313]
Chiasson JL, Josse RG, Gomis R et al.. “Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.” Lancet (London, England) (2002). PMID: 12086760 ↗
L1RCTCited in: History and Evolution of Treatment
[314]
Gaede P, Vedel P, Parving HH et al.. “Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.” Lancet (London, England) (1999). PMID: 10030326 ↗
L1RCTCited in: History and Evolution of Treatment
[315]
Gallwitz B, Rosenstock J, Rauch T et al.. “2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.” Lancet (London, England) (2012). PMID: 22748821 ↗
L1RCTCited in: History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[316]
Yan H, Liu J, Zhang Z et al.. “Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.” Diabetologia (2026). PMID: 41735586 ↗
L1RCTCited in: History and Evolution of Treatment
[317]
Drenthen LCA, de Baaij JHF, Rodwell L et al.. “Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.” Diabetologia (2023). PMID: 37922013 ↗
L1RCTCited in: History and Evolution of Treatment
[318]
Cao J, Yan W, Ma X et al.. “Insulin-like Growth Factor 2 mRNA-Binding Protein 2-a Potential Link Between Type 2 Diabetes Mellitus and Cancer.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34061963 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[319]
Tokoro MF, Mita T, Osonoi Y et al.. “An evening chronotype is associated with the incidence and progression of diabetic retinopathy in people with type 2 diabetes mellitus: a cohort study.” Diabetologia (2025). PMID: 41134330 ↗
L2COHORTCited in: History and Evolution of Treatment
[320]
Tobias DK, Gaskins AJ, Missmer SA et al.. “History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study.” Diabetologia (2015). PMID: 25596853 ↗
L2COHORTCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[321]
Scairati R, Auriemma RS, Di Meglio S et al.. “Risk Assessment of Diabetes Mellitus During and After Pregnancy in Women With Prolactinomas.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38693775 ↗
L4OTHERCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[322]
Pokharel P, Bellinge JW, Dalgaard F et al.. “Vitamin K1 Intake and Incident Diabetes in the Danish Diet, Cancer, and Health Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37235778 ↗
L2OTHERCited in: History and Evolution of Treatment
[323]
Yland JJ, Huybrechts KF, Wesselink AK et al.. “Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus.” Diabetes care (2024). PMID: 39042587 ↗
L2OTHERCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[324]
Batterham RL, Cummings DE. “Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery.” Diabetes care (2016). PMID: 27222547 ↗
L5OTHERCited in: History and Evolution of Treatment
[325]
Ipsen EØ, Madsen KS, Chi Y et al.. “Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 33210751 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[326]
Nield L, Summerbell CD, Hooper L et al.. “WITHDRAWN: Dietary advice for the prevention of type 2 diabetes mellitus in adults.” The Cochrane database of systematic reviews (2016). PMID: 26790033 ↗
L5SR_OBSCited in: History and Evolution of Treatment
[327]
Pappas Y, Wei I, Car J et al.. “Computer-assisted versus oral-and-written family history taking for identifying people with elevated risk of type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2011). PMID: 22161431 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[328]
Steinsbekk A, Rygg LØ, Lisulo M et al.. “WITHDRAWN: Group based diabetes self-management education compared to routine treatment, waiting list control or no intervention for people with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2015). PMID: 26125655 ↗
L5SR_OBSCited in: History and Evolution of Treatment
[329]
Semlitsch T, Engler J, Siebenhofer A et al.. “(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 33166419 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[330]
Wullaert A, van Loo G, Heyninck K et al.. “Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond.” Endocrine reviews (2007). PMID: 17431229 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[331]
Tamir TT, Zegeye AF, Tekeba B et al.. “Global evidence on risk factors for the progression of gestational diabetes to type 2 diabetes: an umbrella review of systematic reviews and meta-analyses.” Diabetology & metabolic syndrome (2026). PMID: 42304503 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Special Populations, Pregnancy and Fertility
[332]
Salgado-Castillo C, García-Mera C, Hernández-Leal MJ et al.. “Mapping research trends in shared decision-making for type 2 diabetes mellitus: a bibliometric study.” Frontiers in health services (2026). PMID: 42291693 ↗
L5SR_OBSCited in: History and Evolution of Treatment
[333]
Chlebek C, Bussberg V, Narain NR et al.. “Baseline serum metabolites predict fractures in individuals who were Black and had type 2 diabetes.” Frontiers in endocrinology (2026). PMID: 42312207 ↗
L2RCTCited in: History and Evolution of Treatment
[334]
Thu SYW, Patnaik S, Shih YH. “Yoga and High-Intensity Interval Training Show Comparable Effects on HbA1c in Type 2 Diabetes: A Systematic Review and Preliminary Pilot Network Meta-Analysis in Adult Populations.” Healthcare (Basel, Switzerland) (2026). PMID: 42354561 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[335]
Liu S, Gao Z, Wang J et al.. “A bibliometric analysis of research on the anti-obesity effects of curcumin from 2006 to 2025: knowledge structure, research hotspots, and evolution of frontiers.” Frontiers in nutrition (2026). PMID: 42293211 ↗
L5SR_OBSCited in: History and Evolution of Treatment
[336]
Soria-Contreras DC, Wang S, Liu J et al.. “Lifetime history of gestational diabetes and cognitive function in parous women in midlife.” Diabetologia (2024). PMID: 39240352 ↗
L2OTHERCited in: History and Evolution of Treatment
[337]
Gan Y, Chen M, Xiao Z et al.. “Nonlinear association between serum insulin, visceral fat area, and kidney function in female with type 2 diabetes: a retrospective study.” Frontiers in endocrinology (2026). PMID: 42305269 ↗
L2COHORTCited in: History and Evolution of Treatment
[338]
Yang M, Liu R, Li S et al.. “Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes.” Diabetes care (2012). PMID: 23275352 ↗
L2RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[339]
Özcan B, Neggers SJ, Miller AR et al.. “Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?” European journal of endocrinology (2013). PMID: 23864339 ↗
L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[340]
Pittas AG, Lau J, Hu FB et al.. “The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17389701 ↗
L2SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[341]
Salley KE, Wickham EP, Cheang KI et al.. “Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.” The Journal of clinical endocrinology and metabolism (2007). PMID: 18056778 ↗
L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[342]
Mahmoudieh L, Amiri M, Rahmati M et al.. “Idiopathic Hirsutism and Metabolic Status: A Population-based Prospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 36125321 ↗
L2COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[343]
Pistrosch F, Matschke JB, Schipp D et al.. “Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.” Diabetologia (2021). PMID: 34495376 ↗
L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[344]
DeBoer MD, Gurka MJ, Woo JG et al.. “Severity of the metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the Princeton Lipid Research Cohort Study.” Diabetologia (2015). PMID: 26380985 ↗
L2COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[345]
Misra A, Khurana L. “Obesity and the metabolic syndrome in developing countries.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18987276 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[346]
Buch A, Marcus Y, Shefer G et al.. “Approach to Obesity in the Older Population.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34406394 ↗
L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[347]
Chen J, Yuan S, Fu T et al.. “Gastrointestinal Consequences of Type 2 Diabetes Mellitus and Impaired Glycemic Homeostasis: A Mendelian Randomization Study.” Diabetes care (2023). PMID: 36800530 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[348]
Hartstra AV, Bouter KE, Bäckhed F et al.. “Insights into the role of the microbiome in obesity and type 2 diabetes.” Diabetes care (2015). PMID: 25538312 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History and Prevention
[349]
Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗
L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[350]
Hoang T, Kim J. “Efficacy and Safety of Probiotics, Prebiotics, and Synbiotics: An Umbrella Review of Systematic Reviews and Meta-Analysis of Randomized Controlled Trials.” Nutrition reviews (2026). PMID: 42289829 ↗
L1SR_MA_RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Special Populations, Pregnancy and Fertility
[351]
Paz-Barba M, Muñoz Garcia A, de Winter TJJ et al.. “Apolipoprotein L genes are novel mediators of inflammation in beta cells.” Diabetologia (2023). PMID: 37924378 ↗
L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[352]
Bruno RM, Penno G, Daniele G et al.. “Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction.” Diabetologia (2012). PMID: 22411135 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[353]
Liu Q, Tang B, Zhu Z et al.. “A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome.” Diabetologia (2022). PMID: 35771237 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[354]
Raghavan S, Porneala B, McKeown N et al.. “Metabolic factors and genetic risk mediate familial type 2 diabetes risk in the Framingham Heart Study.” Diabetologia (2015). PMID: 25619168 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[355]
Garcia-Ravelo KF, Martagon AJ, Galán-Ramírez GA et al.. “Association between perceived stress and metabolic parameters: a systematic review and meta-analysis.” Diabetology & metabolic syndrome (2026). PMID: 42365351 ↗
L2SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[356]
Liu Y, Yang M, Liao Y et al.. “Global research trends, reporting and handling of missing data in observational studies of type 2 diabetes mellitus with mild cognitive impairment from 2020 to 2025: a systematic review.” Frontiers in endocrinology (2026). PMID: 42199803 ↗
L5SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[357]
Smith RL, Soeters MR, Wüst RCI et al.. “Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease.” Endocrine reviews (2018). PMID: 29697773 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[358]
Orozco LJ, Buchleitner AM, Gimenez-Perez G et al.. “Exercise or exercise and diet for preventing type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2008). PMID: 18646086 ↗
L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects
[359]
Song R, Hu W, Cheng R et al.. “Association Between Circulating Levels of C1q/TNF-Related Protein-9 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37029975 ↗
L3SR_OBSCited in: Complications and Long-term Sequelae
[360]
Hsiao YY, Chen YY, Kuo MJ et al.. “SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39998428 ↗
L2COHORTCited in: Complications and Long-term Sequelae
[361]
Hong S, Park JH, Han K et al.. “Association Between Obesity and Cardiovascular Disease in Elderly Patients With Diabetes: A Retrospective Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34597374 ↗
L2COHORTCited in: Complications and Long-term Sequelae, Special Populations, Pregnancy and Fertility
[362]
Wijnen M, Olsson DS, van den Heuvel-Eibrink MM et al.. “Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study.” European journal of endocrinology (2017). PMID: 29046325 ↗
L2COHORTCited in: Complications and Long-term Sequelae
[363]
Cho J, Woo S, Hwang SH et al.. “A Multimodal Predictive Model for Chronic Kidney Disease and Its Association With Vascular Complications in Patients With Type 2 Diabetes: Model Development and Validation Study in South Korea and the U.K.” Diabetes care (2025). PMID: 40590639 ↗
L2OTHERCited in: Complications and Long-term Sequelae
[364]
Kaze AD, Ndumele CE, Martin SS et al.. “Visit-to-Visit Variability in Lipid Levels and Risk of Incident Heart Failure in Adults With Type 2 Diabetes.” Diabetes care (2025). PMID: 40227864 ↗
L2OTHERCited in: Complications and Long-term Sequelae
[365]
Mazzone T, Chait A, Plutzky J. “Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.” Lancet (London, England) (2008). PMID: 18502305 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae
[366]
Hayes AJ, Leal J, Gray AM et al.. “UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.” Diabetologia (2013). PMID: 23793713 ↗
L2OTHERCited in: Complications and Long-term Sequelae
[367]
Hu X, Guo F. “Amino Acid Sensing in Metabolic Homeostasis and Health.” Endocrine reviews (2021). PMID: 33053153 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae, Prognosis, Natural History and Prevention
[368]
Batista PG, Dos Santos Silva RRA, Montenegro MV et al.. “GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 42387250 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae
[369]
Rosenzweig JL, Ferrannini E, Grundy SM et al.. “Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18664543 ↗
L1GUIDELINECited in: Prognosis, Natural History and Prevention
[370]
Zhang Y, Tan H, Tang J et al.. “Effects of Vitamin D Supplementation on Prevention of Type 2 Diabetes in Patients With Prediabetes: A Systematic Review and Meta-analysis.” Diabetes care (2020). PMID: 33534730 ↗
L1SR_OBSCited in: Prognosis, Natural History and Prevention
[371]
Frye RL, August P, Brooks MM et al.. “A randomized trial of therapies for type 2 diabetes and coronary artery disease.” The New England journal of medicine (2009). PMID: 19502645 ↗
L1RCTCited in: Prognosis, Natural History and Prevention
[372]
Zandbergen AA, Lamberts SW, Janssen JA et al.. “Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I.” European journal of endocrinology (2006). PMID: 16868143 ↗
L4TRIAL_NONRANDOMCited in: Prognosis, Natural History and Prevention
[373]
Bo S, Gentile L, Castiglione A et al.. “C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.” European journal of endocrinology (2012). PMID: 22577110 ↗
L2COHORTCited in: Prognosis, Natural History and Prevention
[374]
Lundgrin EL, Hatipoglu B. “Trending Modalities in Type 2 Diabetes Prevention.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39998920 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
[375]
Al-Aubaidy HA, Jelinek HF. “Oxidative DNA damage and obesity in type 2 diabetes mellitus.” European journal of endocrinology (2011). PMID: 21436346 ↗
L3OTHERCited in: Prognosis, Natural History and Prevention
[376]
Ferreira JP, Lamiral Z, Xhaard C et al.. “Circulating plasma proteins and new-onset diabetes in a population-based study: proteomic and genomic insights from the STANISLAS cohort.” European journal of endocrinology (2020). PMID: 32567559 ↗
L2OTHERCited in: Prognosis, Natural History and Prevention
[377]
Mayer-Davis EJ, Lawrence JM, Dabelea D et al.. “Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.” The New England journal of medicine (2017). PMID: 28402773 ↗
L2OTHERCited in: Prognosis, Natural History and Prevention
[378]
Yoon NA, Diano S. “Hypothalamic glucose-sensing mechanisms.” Diabetologia (2021). PMID: 33544170 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention
[379]
Rodrigues de Oliveira Filho J, Bregion PB, Juca RH et al.. “GERD remission and safety profile of Single Anastomosis Sleeve Ileal (SASI) bypass vs sleeve gastrectomy (SG): a systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42377474 ↗
L2SR_OBSCited in: Prognosis, Natural History and Prevention
[380]
Karczewski D, Karczewski T, Olsen M. “Glycated Hemoglobin and Prediabetes: A Systematic Review of HbA1c Thresholds for Type 2 Diabetes Prevention.” Journal of clinical medicine (2026). PMID: 42355858 ↗
L2SR_OBSCited in: Prognosis, Natural History and Prevention
[381]
Palomba S, Falbo A, Zullo F et al.. “Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.” Endocrine reviews (2008). PMID: 19056992 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History and Prevention, Special Populations, Pregnancy and Fertility
[382]
Nield L, Summerbell CD, Hooper L et al.. “Dietary advice for the prevention of type 2 diabetes mellitus in adults.” The Cochrane database of systematic reviews (2008). PMID: 18646120 ↗
L1SR_OBSCited in: Prognosis, Natural History and Prevention
[383]
Al Nofal A, Benkhadra K, Abbas A et al.. “A Systematic Review Supporting the Clinical Practice Guidelines on the Management of Preexisting Diabetes and Pregnancy.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652449 ↗
L1GUIDELINECited in: Special Populations, Pregnancy and Fertility
[384]
Zhong VW, Juhaeri J, Cole SR et al.. “Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2017). PMID: 28716781 ↗
L3COHORTCited in: Special Populations, Pregnancy and Fertility
[385]
Karstoft K, Clark MA, Jakobsen I et al.. “Glucose effectiveness, but not insulin sensitivity, is improved after short-term interval training in individuals with type 2 diabetes mellitus: a controlled, randomised, crossover trial.” Diabetologia (2017). PMID: 28842722 ↗
L1RCTCited in: Special Populations, Pregnancy and Fertility
[386]
Bao W, Yeung E, Tobias DK et al.. “Long-term risk of type 2 diabetes mellitus in relation to BMI and weight change among women with a history of gestational diabetes mellitus: a prospective cohort study.” Diabetologia (2015). PMID: 25796371 ↗
L2COHORTCited in: Special Populations, Pregnancy and Fertility
[387]
Joham AE, Ranasinha S, Zoungas S et al.. “Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24081730 ↗
L4OTHERCited in: Special Populations, Pregnancy and Fertility
[388]
Retnakaran R, Shah BR. “Role of Type 2 Diabetes in Determining Retinal, Renal, and Cardiovascular Outcomes in Women With Previous Gestational Diabetes Mellitus.” Diabetes care (2016). PMID: 27821407 ↗
L3OTHERCited in: Special Populations, Pregnancy and Fertility
[389]
Yoshida Y, Chen Z, Baudier RL et al.. “Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women.” Diabetes care (2021). PMID: 34475032 ↗
L2OTHERCited in: Special Populations, Pregnancy and Fertility
[390]
Morrison KM, Xu L, Tarnopolsky M et al.. “Screening for dysglycemia in overweight youth presenting for weight management.” Diabetes care (2012). PMID: 22271926 ↗
L4OTHERCited in: Special Populations, Pregnancy and Fertility
[391]
Kramer CK, Swaminathan B, Hanley AJ et al.. “Each degree of glucose intolerance in pregnancy predicts distinct trajectories of β-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum.” Diabetes care (2014). PMID: 25231898 ↗
L2OTHERCited in: Special Populations, Pregnancy and Fertility
[392]
Pellitero S, Reverter JL, Granada ML et al.. “Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.” European journal of endocrinology (2009). PMID: 19304869 ↗
L4OTHERCited in: Special Populations, Pregnancy and Fertility
[393]
Vitezova A, Zillikens MC, van Herpt TT et al.. “Vitamin D status and metabolic syndrome in the elderly: the Rotterdam Study.” European journal of endocrinology (2014). PMID: 25468955 ↗
L4OTHERCited in: Special Populations, Pregnancy and Fertility
[394]
Awa WL, Fach E, Krakow D et al.. “Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV database.” European journal of endocrinology (2012). PMID: 22645200 ↗
L4OTHERCited in: Special Populations, Pregnancy and Fertility
[395]
Sparks JR, Ghildayal N, Hivert MF et al.. “Lifestyle interventions in pregnancy targeting GDM prevention: looking ahead to precision medicine.” Diabetologia (2022). PMID: 35150287 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy and Fertility
[396]
Ravnsborg T, Andersen LL, Trabjerg ND et al.. “First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry.” Diabetologia (2016). PMID: 26818149 ↗
L3OTHERCited in: Special Populations, Pregnancy and Fertility
[397]
Lloyd M, Morton J, Teede H et al.. “Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to reduce the incidence of gestational diabetes and type 2 diabetes.” Diabetologia (2023). PMID: 36932207 ↗
L5OTHERCited in: Special Populations, Pregnancy and Fertility
[398]
Derse TK, Kide DM, Asgai AS et al.. “Metabolic trajectory from gestational to type 2 diabetes mellitus: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42218942 ↗
L2SR_OBSCited in: Special Populations, Pregnancy and Fertility
[399]
Tieu J, Middleton P, Crowther CA et al.. “Preconception care for diabetic women for improving maternal and infant health.” The Cochrane database of systematic reviews (2017). PMID: 28799164 ↗
L1SR_OBSCited in: Special Populations, Pregnancy and Fertility
[400]
Han S, Middleton P, Shepherd E et al.. “Different types of dietary advice for women with gestational diabetes mellitus.” The Cochrane database of systematic reviews (2017). PMID: 28236296 ↗
L1SR_OBSCited in: Special Populations, Pregnancy and Fertility
[401]
Öner MÖ, Aslan F, Binici S et al.. “Safety and Metabolic Outcomes of Three-Port Laparoscopic Sleeve Gastrectomy Without Liver Retractor: A 2000-Patient Retrospective Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356128 ↗
L4COHORTCited in: Special Populations, Pregnancy and Fertility
[402]
Zhang H, Chen D, Song Q et al.. “Staged antibiotic-loaded cement-based reconstruction versus flap-based reconstruction for complex diabetic foot defects in patients with osteoporosis: a retrospective cohort study.” Frontiers in surgery (2026). PMID: 42245312 ↗
L2COHORTCited in: Special Populations, Pregnancy and Fertility
[403]
Travis LM, Kimbrough DW, Samineni AV et al.. “Effect of hemoglobin A1c levels on 30-day complications after elective anterior cervical discectomy and fusion: a retrospective cohort study.” Journal of spine surgery (Hong Kong) (2026). PMID: 42158068 ↗
L2COHORTCited in: Special Populations, Pregnancy and Fertility
[404]
Jang K, Zeitler PS. “Prediabetes in children and adolescents: what do we need to know?” Annals of pediatric endocrinology & metabolism (2026). PMID: 42415555 ↗
L5OTHERCited in: Special Populations, Pregnancy and Fertility

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification and Axis Nomenclature

Axis Physiology, Pathophysiology and Biochemical Signature

The Pathophysiologic Chain: Five Linked Failures

Biochemical Signature

Epidemiology, Etiology and Risk Factors

Risk Factors

Temporal Trends

Clinical Presentation

Presenting Symptoms

Neurological Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization

Establishing the Diagnosis

Dynamic Testing: The Oral Glucose Tolerance Test

Additional Biochemical Assessment

Screening in Special Populations

Role of Imaging

Diagnostic Algorithm

Controversies and Guideline Disagreement

Severity, Staging and Risk Stratification

Age at Diagnosis as a Dominant Risk Driver

Cardiovascular Risk Scores

Insulin Requirement and Disease Burden

Clustering and Subphenotypes

Fasting C‑Peptide Index and Vascular Phenotypes

Organ‑Specific Risk Stratification

Integration Into Clinical Practice

Acute Management and Endocrine Emergencies

Step 1: Diagnosis and Severity Classification

Step 2: Fluid Resuscitation

Step 3: Insulin Therapy

Step 4: Potassium and Electrolyte Monitoring

Step 5: Transition to Subcutaneous Insulin

Special Considerations

Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)

Step 1: Lifestyle Intervention as Foundation

Step 2: First-Line Pharmacotherapy, Metformin

Step 3: Add-On Therapy with Cardiorenal Benefit

Step 4: Intensification with Additional Agents

Step 5: Definitive Therapy, Metabolic Surgery

Treatment Failure Protocol

What NOT to Do

Controversies and Guideline Disagreement

History and Evolution of Treatment

The Metformin Era and the UKPDS Legacy

The Thiazolidinedione Promise and Peril

Cardiovascular Safety Mandates and the DPP-4i Lesson

The SGLT2i and GLP-1 RA Revolution

Evolving Prevention and Lifestyle Strategies

Abandoned Pathways and Lessons Learned

Multiglandular Syndromes, Genetic Context and Co-Axis Effects

Polycystic Ovary Syndrome (PCOS)

Metabolic Syndrome and Familial Aggregation

Adrenal Axis: Mild Autonomous Cortisol Secretion (MACS)

Thyroid and Other Endocrine Axes

Genetic Syndromes

Gut Microbiome, Incretin Axis, and Nutritional Factors

Inflammation and Cellular Senescence

Hyperuricemia and Gout

Complications and Long-term Sequelae

Macrovascular Complications

Microvascular Complications

Infection and Cognitive Dysfunction

Complications Overview

Controversies and Guideline Disagreement

Prognosis, Natural History and Prevention

Primary Prevention

Screening and Risk Stratification

Controversies and Guideline Disagreement

Special Populations, Pregnancy and Fertility

Step 2: First-Line Pharmacotherapy,

The Era and the UKPDS Legacy

Fertility, , and Cardiometabolic Risk